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Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in patients 
admitted to the ICU and a leading cause of mortality in critically ill patients. The rise in antimicrobial 
resistance threatens current treatment methods, and if not addressed will lead to a significant 
increase in mortality. Rapid and accurate diagnostic methodologies are needed to combat this 
issue. To develop and test the potential of these DNA based technologies, we focus here on 
Staphylococcus aureus as it is a common cause of antimicrobial resistant VAP. 
The first step in the application of any DNA-based test is the reliable extraction of the bacterial 
DNA. In this project three DNA extraction methods were compared for accuracy and sensitivity: a 
commercially available DNA extraction kit, and two methods which use traditional 
phenol/chloroform methods for DNA purification but differ in their lysis technique; one using 
physical bead-beating and the other using MetaPolyzyme, a multi-lytic enzyme mix. 
To test each method’s ability to extract S. aureus, extracted DNA was amplified using qPCR with 
generic 16S rRNA gene primers and S. aureus specific nuc gene primers to determine the relative 
quantity of S. aureus within a sample. On pure broth grown cultures the bead-beating method was 
determined as the most effective and was subsequently developed and optimised for use on 
pleural fluids provided to us by the NHS. With these more complex materials the use of phase lock 
gel (PLG) reduced the variability observed when using phenol/chloroform in standard laboratory 
tubes. 
Having established the optimal extraction methodology, and alongside control plasmids, the limit of 
detection was determined for two sets of PCR primers, a generic bacterial 16S set and a S. aureus 
specific nuc set. The limit of detection of spiked pleural fluids was ~1x104 CFU/ml using the 16S 
primer set and ~1x103 CFU/ml for the nuc set. As this work is developed further its use in a clinical 
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Pneumonia is defined as inflammation of the tissue in the lungs, usually due to a bacterial infection 
[1], the swelling causes areas of the lung to become consolidated and fill with liquid, causing loss 
of function. The healthy lung contains complex communities of commensal microorganisms with 
microbe-microbe and microbe-host interactions contributing to the maintenance of the healthy state 
of the lung; commensals are thought to confer protection from respiratory pathogens by inducing a 
constant, low-scale response from the host’s immune system, preventing an infection from being 
established [2]. However, competition between commensal organisms can lead to the development 
of infection by one of these commensal species, blurring the boundary between commensal and 
pathogen [3]. The complexity of the human lung microbiome is known to be intricately involved in 
the development of pneumonia [4], however there is currently a significant gap in this area of 
research [3]. 
 
1.2. The lung microbiome 
Microbiome research is one of the fastest growing areas of cutting-edge investigation and our 
understanding of the complex relationships between human and microbial life is rapidly expanding. 
Recent advances in molecular techniques, such as the advent of next generation sequencing, 
have enabled a new depth of understanding in this area. For many years, the healthy human lung 
was considered a sterile organ [5]; this inference was likely due to the difficulties in examining the 
composition of the lung exclusively through culture-dependent techniques. The complexity of the 
lung environment provides an example of an in-host location creating a niche for many viable but 
not culturable organisms [6, 7]. Replicating a culturable environment for these organisms is difficult 
due to the range of conditions found within the lung, from the oxygen availability gradient, to pH, 
temperature and nutrient availability gradients, all of which provide selective pressures influencing 
the precise microbial communities able to occupy this niche. Furthermore, host immune factors 
change with distance into the lower respiratory tract, as does local competition of microbial life 
found here [8]. The culmination of all these factors leads to a difficult environment to simulate in 
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vitro. Advances in culture independent techniques enable us to remove a sample from any location 
within the lower respiratory tract, isolate the total DNA within that sample and analyse its 
composition through qPCR and rapid next-generation sequencing techniques. Genetic-based 
approaches have shown that the human lung contains approximately 2.2 x 103 bacterial genomes 
per cm2 (assuming 1 copy of the 16S rRNA gene per genome) [9], with most microorganisms 
present belonging to four phyla: Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria [10]. 
For a typical, healthy individual, the most common genera present in the lungs are 
Corynebacterium, Prevotella, Staphylococcus, Streptococcus, Veillonella, Haemophilus and 
Neisseria [9]. The discovery that the lungs do have a distinct, natural microbiome has prompted 
further research into the dynamics of the microorganisms residing in this highly dynamic 
environment. 
Diseased states are strongly correlated with dysbiosis, or imbalance, of the natural pulmonary 
equilibrium [11-13]. One of the leading models for the ecology of the lung microbiome is the 
adapted island model [14] (Figure 1); this model is based on a well-established model of island 
ecology and suggests that the microbial movement within the lungs follows similar patterns to 
migration of animals between land masses. The model states that a main population resides on the 
mainland, and over time, individuals will migrate from the mainland to the islands. The closer an 
island is to the mainland, the higher the likelihood of migration, resulting in a stratified series of 
populations on islands where each resembles the mainland more similarly than subsequent, more 
distant islands. This directly impacts species richness in each location, with species richness 
decreasing with distance from the main population, and every species present at the furthest island 
must have passed by the closer islands first. 
The adapted island model adjusts this theory to fit the respiratory tract; the upper tract takes the 
place of the mainland and is the source of all species found in the lower tract, which takes the 
place of the islands. For any given site along a healthy respiratory tract, microbial species richness 
is mostly determined by immigration and elimination of microbes originating in the upper 
respiratory tract. The lung microbiome is maintained through an equilibrium of immigration via 
microaspiration of microorganisms in the air, and elimination through standard mucociliary action 
3 
 
and coughing. This allows a steady change in the microbiome over time, whilst maintaining a core 
lung microbiome of common microorganisms. If this equilibrium is compromised, regional growth 
conditions become a more significant factor for determining the composition of the microbiome. 
Dysbiosis of the lungs can produce an opening for opportunistic pathogens to establish an 
infection, leading to inflammation of the lungs and the development of pneumonia. 
 
 
Figure 1 –  Adapted island model of the respiratory microbiome: The three factors which determine 
the respiratory microbiome (immigration, elimination, and relative growth of organisms) and their 
relationship with health and disease. (Source: Dickson et al., 2015)[14]. 
 
1.3. Ventilator-associated pneumonia 
Any condition resulting in a patient becoming unable to breathe unassisted requires artificial 
ventilation, this is one of the largest changes which can occur in the lungs, significantly impacting 
the environment for the commensal organisms present. If pneumonia develops more than 48 hours 
after intubation, it is termed ventilator-associated pneumonia (VAP) [15]. The effect of intubation on 
the lung microbiome is not fully understood, however intubation is highly likely to affect the 
equilibrium between microbial immigration and elimination, and the ventilator itself provides a new 
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environment which can be colonised. Any changes to the composition of commensal 
microorganisms present in the lung may enable the establishment of an opportunistic infection; it 
has been shown that the level of dysbiosis in the lungs following intubation is more profound in 
patients who develop VAP compared to those who do not develop pneumonia [16]. 
Microbial load of the lung is typically determined from samples of bronchoalveolar lavage (BAL) 
fluid, and pneumonia is diagnosed when the load rises above a threshold of 104 colony forming 
units per ml (CFU/ml) [17]. BAL is collected by introducing 130 to 150ml of sterile saline into the 
lungs before collecting and examining the contents through traditional culture methods. It is 
considered the gold standard for research into microbial communities in the lower respiratory tract 
as BAL fluid has been shown to have the same microbial composition as the lung tissue microbiota 
itself [18]. 
Pneumonia is typically treated using antibiotics to clear the infection, with VAP accounting for 
almost half of all antibiotics given in intensive care units (ICU’s) [19, 20] due to it being the most 
common nosocomial infection in patients admitted to the ICU [16] and a leading cause of mortality 
in critically ill patients [21]. Each year, between 10,000 and 20,000 patients in the UK [22] and 
between 250,000 and 300,000 patients in the USA are diagnosed with VAP [23]. Clinical reliance 
on antibiotics for treatment combined with the increasing prevalence of antimicrobial resistance 
has significantly impaired our ability to treat these infections effectively. In order to adapt treatment 
strategies to be more efficient and sustainable, further research must be carried out to determine 
the dynamics of the opportunistic pathogens responsible for VAP in the periods prior to and during 
diseased states. 
 
1.4. Staphylococcal pneumonia 
Staphylococcus aureus is consistently one of the most important causes of nosocomial infection 
and VAP [24, 25]. It is one of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species) which have been identified as the leading causes of nosocomial infection 
throughout the world [26]. This opportunistic pathogen is highly successful in establishing infection 
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due to a number of important virulence factors, including staphylococcal protein A (SpA) which is 
one of the most abundant proteins on the surface of S. aureus [27] and mediates binding to a 
membrane protein on the lung epithelium, Tumour Necrosis Factor Receptor 1 (TNFR1) [28]. This 
binding leads to a severe inflammatory response in the lungs which is a hallmark of pneumonia. 
Furthermore, the increase in antibiotic resistance is a severe complication for the treatment of 
bacterial infections. After a patient has received antibiotic treatment, if they then develop VAP it is 
far more likely that the causative strain will be resistant to further antibiotics [29], significantly 
increasing the likelihood of mortality. 
As a major threat to public health and one of the most commonly reported pathogens associated 
with ventilator-associated pneumonia (VAP) [30], S. aureus pneumonia is an ideal model to use 
when investigating the dynamics of an opportunistic pathogen throughout the entire infection-to-
disease process. One potential caveat of using staphylococcal species in studies such as this is 
that it is notoriously difficult to accurately and consistently extract DNA from [31, 32]. Difficulties in 
staphylococcal DNA extractions are due this organism’s complex cell wall and its ability to form 
biofilms which can prevent chemical and biological agents for cellular lysis from reaching all cells in 
a population. Therefore, if the DNA extraction technique used is sensitive enough to accurately and 
consistently extract DNA from a difficult to lyse organism such as S. aureus, then the DNA from all 
other species within the sample should also be extracted, giving a representative view of the 
sample composition. 
To further research on the dynamics of staphylococcal pneumonia, it is essential to have an 
accurate and reliable method for extracting DNA from pulmonary clinical samples, such as BAL. 
This will be vital as culture independent techniques become the new paradigm for microbial 
research, especially in the context of the microbiome. Microbiome studies commonly use the 16S 
rRNA gene as a genetic barcode to identify species. To understand the dynamics of MRSA within 
a microbiome environment, it will be essential to extract all microbial DNA and assess the 
composition, with specific regard to the proportion of DNA within each sample which is 
staphylococcal in origin. In a longitudinal study, this would allow observation of the dynamics of this 
organism in the reference frame of the wider lung microbiome. 
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It is especially important to be able to collect an accurate representation of organisms with low 
prevalence in the lung microbiota at the beginning of longitudinal studies in order to give a clear 
picture of how the dynamics have changed. Determining whether the organism which causes the 
potentially lethal pneumonia was present in the patient’s lung upon hospital entry or if it was 
acquired whilst in care could be a vital piece of information when determining the correct course of 
clinical care to prevent future infections. This also has implications on the stewardship of antibiotics 
which may treat non-life-threatening infections whilst simultaneously enabling antimicrobial 
resistant opportunistic pathogens to establish subsequent infections. 
 
1.5. DNA extraction methods 
It is important that DNA extraction from clinical samples of unknown composition must be as 
comprehensive as possible, enabling extraction of DNA from all microbes within a sample with as 
high efficacy as possible. Imbalances in extraction efficiencies at an early stage of any project 
reliant on genetic techniques will lead to erroneous results. Once the total DNA has been extracted 
from clinical pulmonary samples, the composition of the sample can be determined by amplifying 
the 16S rRNA gene which is universal to all bacterial species. Small variations within the variable 
regions of the 16S rRNA gene allow it to be used as a barcode to determine which species a 
specific sequence originates from. The 16S rRNA gene can be amplified using traditional PCR 
methods, and the amplified product sequenced to determine the species present within a sample. 
qPCR is a type of PCR which enables quantification of a product throughout the amplification cycle 
by detecting the level of a fluorescent signal produced by the product amplified during a reaction; 
this enables quantification of the organisms present in a sample based on their 16S copy number 
when compared to a standard of a known quantity. 
There are many different methods by which DNA can be extracted, however methods can be 
biased for or against groups of organisms and can introduce contaminants which may affect 
downstream applications [33]. DNA extraction methods include applying physical force, enzymes, 
detergents, heat, freeze-thaw cycles, microwaves or sonication to lyse cells; followed by 
purification using spin columns, magnetic beads or the chemical properties of DNA to purify it via a 
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series of steps exploiting its differential solubility to other components within a sample. It is now 
very common to use specifically manufactured commercial kits which contain all reagents needed 
to extract DNA from a sample. 
It is integral to any study reliant on 16S rRNA sequencing that the extraction method must provide 
an accurate depiction of the microbial composition in each sample. It is important to note that 
testing the DNA in a sample directly introduces far less bias than traditional culture methods, as 
well as permitting quantification of organisms and investigation of viable but not culturable 
organisms. 
 
1.6. DNA extraction from Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive organism, the cell wall of Gram-positive species 
consists of a cytoplasmic cell membrane surrounded by a thick peptidoglycan layer (figure 2). This 
thick layer of peptidoglycan makes Gram-positive organisms significantly more difficult to lyse [34]. 
Even compared to other Gram-positive bacteria, S. aureus has a complex cell wall structure 
(Figure 3) due to its highly cross-linked peptidoglycan structure containing cross-linking peptides 
and teichoic acids which improve the rigidity of the cell wall [35]. Many S. aureus strains form a 
polysaccharide capsule which reinforces cellular integrity, making the organism even more robust 
[36]. Furthermore, S. aureus commonly forms complex multi-layered biofilms, leading to members 
of a community being physically protected by other members as well as an extracellular matrix 
which benefits the whole community [37]. The combination of these factors results in S. aureus 
being a highly robust organism and a difficult target for DNA extraction. Therefore, it is an ideal 
candidate for this study, as if S. aureus in the clinical samples is successfully lysed, it can be 
assumed that all other organisms will have also been lysed, giving an accurate representation of 




Figure 2 - Basic cell wall structures of Gram-positive and Gram-negative bacteria , showing thick 
peptidoglycan layer which makes Gram positive organisms more resistant to cellular lysis (Source: 
The Open University, 2019)[38]. 
 
 
Figure 3 - Staphylococcus aureus cell wall structure showing cross-linking in peptidoglycan layer. 
A shows surface and secreted proteins, B and C show cross-sections of the cell envelope, 
including cross-linking peptides and teichoic acids present in the peptidoglycan layer (Source: 




The primary intention of this project was to develop and optimise a protocol for the extraction of 
microbial DNA from complex pulmonary clinical samples. Staphylococcus aureus was used as a 
model organism for this project as it is an important pulmonary pathogen and is a particularly 
difficult organism to lyse; therefore, if the protocol is successful when used on S. aureus, it can be 
expected to work with a very wide range of microorganisms. The protocol resulting from this project 
will be beneficial if used in the academic setting by advancing the techniques used for microbiome 
research, and will also be beneficial if used in the healthcare setting by improving the efficiency of 
pulmonary infection diagnoses compared to traditional culture based methods. To accomplish this 
main objective, several specific goals must be achieved by answering the questions below. 
Selection of an extraction method: 
1. Is there a difference in extraction ability when implementing a wide-spectrum multi-lytic 
enzyme mix (such as MetaPolyzyme) for use with a commercial DNA extraction kit 
compared to using a species-specific lysis enzyme (such as Lysostaphin)? 
2. Is there a difference in yield when extracting DNA from fresh samples compared to frozen 
samples? 
3. Is a commercial DNA extraction kit more effective than traditional phenol/chloroform 
methods at extracting low-yield microbial DNA? 
4. Is enzymatic lysis more effective than physical/detergent based lysis methods for extracting 
low-yield microbial DNA? 
5. Which of the candidate extraction methods is most effective at extracting DNA from low-
yield microbial samples? 
Development and optimisation of chosen method: 
6. How reliable is this DNA extraction method? 
7. Can application of Phase Lock Gel reduce the variability in results produced when using 
this DNA extraction method? 
8. Is the limit of detection (LoD) of this DNA extraction method on pulmonary samples at least 
comparable to the current clinical cut off for a positive BAL sample (1x104 CFU/ml)? 
9. Does the use of a complex clinical sample impair the efficacy of this DNA extraction method 
and its associated qPCR analysis? 
10. Is it possible to perform absolute quantification of the number of cells present in the initial 
sample when using this DNA extraction method and its associated qPCR analysis? 
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3. Materials and methods 
3.1. Reagents 
Item Manufacturer 
325 mesh silicon dioxide Sigma 
70% ethanol Sigma 
Aluminium ammonium sulphate dodecahydrate Acros Organics 
Chloroform:Isoamyl alcohol (24:1) Sigma 
CTAB (Hexadecyltrimethylammonium bromide) Sigma 
CutSmart restriction enzyme buffer New England Biolabs 
Dimethylsiloxane-350 Mistral 
EcoRI High-Fidelity restriction enzyme New England Biolabs 
GelRed nucleic acid gel stain Biotium 
GeneJET plasmid miniprep kit Thermo Scientific 
GeneJET plasmid miniprep kit Thermo Scientific 
GeneRuler 1kb Thermo Scientific 
GeneRuler 50bp Thermo Scientific 
Genomic DNA clean & concentrator kit Zymo Research 
GoTaq Green PCR master mix Promega 
High-pure PCR template preparation kit Roche 
KAPA HiFi HotStart ReadyMix Roche 
KAPA SYBR FAST qPCR master mix KAPA Biosystems 
KpnI High-Fidelity restriction enzyme New England Biolabs 
Linear polyacrylamide (LPA) Sigma 
Low-EDTA TE buffer Made in-house 
Lysing Matrix E tubes MP Biomedicals 
Lysostaphin Sigma 
MetaPolyzyme multilytic enzyme mix Sigma 
pCDF-Duet-1 plasmid vector Novagen 
PCR grade water Promega 
Phenol:Chloroform:Isoamyl alcohol (24:25:1) Sigma 
Phosphate buffered saline (PBS) Made in-house 
Polyethylene glycol 6000 (PEG) Sigma 
QIAquick PCR purification kit Qiagen 
qPCR grade water Invitrogen 
SYBR Safe DNA gel stain Invitrogen 
T4 DNA ligase New England Biolabs 




Tris-EDTA (TE) buffer Made in-house 
Tryptone soy agar (TSA) Made in-house 
Tryptone soy broth (TSB) Made in-house 
Table 1 – Reagents used and suppliers. Reagents denoted as ‘made in-house’ were produced by 




Centrifuge VWR Microstar 17R 
Electrophoresis powerpac Bio Rad – powerpac 300 
GeneSys UV transilluminator SYNGENE – G:box 
Heat block Techne BRI block DB.2P 
NanoDrop Thermo Scientific - NanoDrop Lite Spectrophotometer 
PCR Thermocycler PCR Max alpha cycler 
qPCR Thermocycler Bio molecular systems – Magnetic induction cycler (mic) 
Ribolyser (Bead-beater) Fast prep hybaid fp120 fp120hy-230 
Shaking incubator New Brunswick Scientific - Innova 44 
Static incubator Leec compact incubator 
Table 2 - Equipment used and suppliers. 
 
3.3. Strains and growth conditions 
For experiments comparing DNA extraction methods, the bacterial strain used was Staphylococcus 
aureus USA300 JE2, taken from a collection owned by Professor Ruth Massey (University of 
Bristol) and cultured using tryptone soy agar (TSA) and tryptone soy broth (TSB). For 
transformation of the Vibrio 16S rRNA gene in a TOPO TA pCR2.1 plasmid and the production of 
the p(nuc) standard, chemically competent DH5α Escherichia coli cells were purchased from 
Invitrogen and cultured using Luria-Bertani agar (LB agar) and Luria-Bertani broth (LB broth). 
Strains were streaked onto agar plates and incubated at 37°C in a static incubator for 18 hours. A 
single colony was then taken from the agar plate and sub-cultured into the appropriate culture 
broth, briefly mixed and then incubated at 37°C in a shaking incubator for 18 hours. 
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3.4. DNA extraction methods 
DNA extraction protocols used: 
• Roche High Pure PCR Template Preparation Kit (Met+Kit) 
• Bead-beating with phenol/chloroform purification (BB+P/C) 
• MetaPolyzyme with phenol/chloroform purification (Met+P/C) 
3.4.1. Roche High Pure PCR Template Preparation Kit 
(“Met+Kit”) 
DNA was extracted from bacterial cells in liquid culture following the manufacturers protocol with 
some minor deviations to improve yield and accuracy for the specific sample types used. 500µl of 
the sample was added to a 1.5ml microcentrifuge tube and centrifuged for 5 minutes at 3,000 x g, 
the pellet was then resuspended in 200µl sterile PBS. To lyse the cells in the sample, 10µl of 
MetaPolyzyme was added (10mg/ml) and incubated for either 15 minutes or 1 hour at 37°C (in a 
static incubator). Following incubation, 200µl of binding buffer and 100µl isopropanol was added 
and the sample was mixed well before being centrifuged for 5 minutes at 13,000 x g. The 
supernatant was transferred to a High Pure filter tube, fitted to a collection tube and centrifuged for 
1 minute at 8,000 x g. At this point, the DNA in the sample has been removed from the cells and 
bound to glass fibres within the filter tube. The following steps are to remove contaminants and 
inhibitors before eluting the purified DNA. 
After centrifugation, flow through liquid was discarded and the filter tube fitted to a new collection 
tube. 500µl inhibitor removal buffer was added before centrifuging for 1 minute at 8,000 x g. After 
centrifugation, flow through liquid was again discarded and a new collection tube fitted before 
adding 500µl wash buffer and centrifuging again for 1 minute at 8,000 x g. This wash step was 
repeated once, then after flow through had been discarded, centrifuged for 10 seconds at full 
speed to remove residual wash buffer. The collection tube was discarded, and the filter tube 
inserted into a clean, sterile 1.5ml microcentrifuge tube. 200µl prewarmed (70°C) elution buffer 
was added and left for 30 minutes at room temperature before being centrifuged for 1 minute at 
8,000 x g to transfer the purified DNA from the filter tube into the microcentrifuge tube. 
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3.4.2. Bead-beating with phenol/chloroform purification 
(“BB+P/C”) 
This protocol was kindly provided by Dr Michael Cox (University of Birmingham). DNA was 
extracted from either bacterial suspension or clinical samples. Sample preparation differs in this 
method depending on sample type. For bacterial isolates, the organism was grown in a 37°C 
shaking incubator for 18 hours in appropriate media, 2ml of this bacterial suspension was then 
centrifuged for 10 minutes at 16,000 x g. For bronchoalveolar lavage (BAL) or pleural fluid (PF), 
5ml was centrifuged for 20 minutes at full speed. 
For all sample types, the pellet was then resuspended in 500µl CTAB buffer and incubated for 15 
minutes at room temperature. Each sample was then transferred into a Lysing Matrix E (LME) tube 
and 50µl aluminium ammonium sulphate (AAS) was added, followed by 500µl 
phenol:chloroform:isoamyl alcohol (PCI). The LME tubes were inserted into a ribolyser and run at a 
speed of 5.5m/sec for 1 minute (2 x 30 second runs). The LME tubes were then centrifuged for 5 
minutes at 16,000 x g. All liquid was then transferred to a fresh 1.5ml microcentrifuge tube 
(containing 100µl phase lock gel for experiments using PLG) and the LME tube was left on ice. 
The microcentrifuge tubes were centrifuged at 4°C for 5 minutes at 16,000 x g, 500µl of 
chloroform:isoamyl alcohol (CI) added, briefly mixed and then centrifuged again at 4°C for 5 
minutes at 16,000 x g. 500µl CTAB buffer, 50µl AAS and 500µl PCI was added to each LME tube 
which had been left on ice, inserted into the ribolyser and the extraction repeated. 
After centrifugation with CI, the aqueous phase from each microcentrifuge tube was transferred to 
pre-prepared fresh 2ml microcentrifuge tubes containing 1µl Linear Polyacrylamide (LPA), 1ml of 
PEG/NaCl added and mixed well. Samples were left at 4°C for 18 hours overnight to precipitate, 
then centrifuged at 4°C for 20 minutes at 16,000 x g. PEG/NaCl was aspirated from the pellets, 
and the pellets then washed with 500µl ice-cold 70% ethanol and centrifuged for 5 minutes at 
16,000 x g. This wash was repeated twice using 200µl ice-cold 70% ethanol, and the pellets air 
dried for 5 minutes before being resuspended in 30µl low-EDTA TE buffer. Resuspended total 
nucleic acid from each sample (primary and secondary extraction) was then combined into a single 
tube as a single 60µl DNA extract per sample. 
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3.4.3. MetaPolyzyme with phenol/chloroform purification 
(“Met+P/C”) 
This method was adapted from the BB+P/C method. The key difference between the two methods 
is the technique used for lysis of bacterial cells within the sample. 
Samples were prepared as above, however once resuspended in 500µl CTAB extraction buffer, 
10µl of MetaPolyzyme (10mg/ml) was added and the sample incubated at 37°C for 1 hour (instead 
of 15 minutes at room temperature. The remainder of the extraction remained the same, except for 
the use of 1.5ml microcentrifuge tubes in place of the LME tubes and the exclusion of the bead-
beating step. Mechanical lysis was not required as MetaPolyzyme causes enzymatic lysis of the 
bacterial cells. This method also excluded the second extraction as the enzymes in the 
MetaPolyzyme mix would be degraded by the phenol already in the sample, rendering a secondary 
lysis stage ineffective. 
 
3.5. DNA quantification and storage 
DNA from all extractions was quantified using a NanoDrop spectrophotometer (Thermo Scientific) 





Primers were purchased from Eurofins Genomics as lyophilised powder. They were diluted to 
100pmol/µl as directed on the oligonucleotide synthesis report provided by Eurofins to produce a 
stock; from this stock they were then diluted to a working concentration of 10pmol/µl. Forward and 
reverse primers for each primer pair were combined. Primers used can be found in Table 3 and 
IUPAC degeneracy codes used in the 16S rRNA primer set can be found in Table 4. The optimal 
annealing temperatures (Ta) for the primers used in traditional PCR were determined by 
temperature gradient PCR runs (shown in Appendix 9.1). 
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Primer Oligonucleotide Sequence 
16S rRNA V4 – 520 (F) 5'- AYTGGGYDTAAAGNG -3’ 
16S rRNA V4 – 802 (R) 5'- TACNVGGGTATCTAATCC -3’ 
nuc_Hoegh (F) 5′- GGGTTGATACGCCAGAAACG -3′ 
nuc_Hoegh (R) 5′- TGATGCTTCTTTGCCAAATGG -3′ 
nuc_qPCR_F 5’- ATTGAAGTCGAGTTTGACAAAG -3’ 
nuc_qPCR_R 5’- TTGTGCTTCACTTTTTCTTAAAAG -3’ 
RD_nuc_F_(EcoRI) 5'- ATAT-GAATTC-CTAAAAAGAAAGAGGTGTTAGTTATGAC -3’ 
RD_nuc_R_(KpnI) 5'- ATAT-GGTACC-GACACTTTTACAATGAGCATTATTG -3’ 
ACYCDuetUP1 5’- GGATCTCGACGCTCTCCCT -3’ 
Table 3 - Primers used for PCR, qPCR and restriction digest procedures. All primers were 
synthesised by Eurofins genomics. Sources: the sequences for the 16S rRNA V4 primers were 
provided by Dr Michael Cox (University of Birmingham); the sequences for the nuc_Hoegh primers 
were taken from literature (Hoegh et al., 2014)[40]; the nuc_qPCR and RD_nuc primer sets were 
designed specifically for this project; and the ACYCDuetUP1 primer was designed by Novagen 
(Merck Group) for pCDF-Duet-1 bacterial vector [41].  




T (or U) Thymine (or Uracil) 
R A or G 
Y C or T 
S G or C 
W A or T 
K G or T 
M A or C 
B C or G or T 
D A or G or T 
H A or C or T 
V A or C or G 
N Any base 
Table 4 – Nucleotide degeneracy codes from the International Union of Pure and Applied 




3.6.2. PCR conditions 
PCR reactions had a total volume of 25µl, comprised of 12.5µl GoTaq MasterMix (Promega), 2.5µl 
forward and reverse primer mix (1:1, each at 10pmol/µl), 2µl template DNA and 8µl PCR grade 
water (VWR). A PCR Max alpha cycler was used to perform the reactions, the conditions used 
unless otherwise stated can be found in Table 5. 
Step Temperature (°C) Time (seconds) Cycles 











Final Extension 72 300 1 
Final Store 4 ∞ - 
Table 5 - PCR reaction conditions used. *Annealing temperatures used differed depending on the 
primer set used: 39.5°C for 16S rRNA primers, 58.2°C for nuc_Hoegh primers. 
3.6.3. Agarose gel electrophoresis 
The PCR products were visualised using electrophoresis on a 1.5% agarose gel. The gel was 
prepared dissolving 1.5g agarose in 100ml 1x TE buffer and then poured into a cradle with SYBR 
Safe gel stain added at 0.1µl/ml. 10µl of each sample was loaded alongside 10µl of Thermo 
Scientific GeneRuler DNA ladder (either 50bp or 1kb) and gels were run at 90V, 300mA for 60 
minutes using a Bio-Rad Power pac 300. Gels were visualised and photographed using a 
GeneSys UV transilluminator. 
3.6.4. Quantitative PCR (qPCR)  
qPCR reactions had a total volume of 20µl, comprised of 10µl KAPA SYBR FAST master mix, 1µl 
of mixed forward and reverse (1:1) primers, 2µl of DNA and 7µl of qPCR grade water (Invitrogen). 




Step Temperature (°C) Time (seconds) Cycles 











Melt conditions (default) 50 to 80 100 (0.3°C/s) 1 
Table 6 – qPCR reaction conditions used. *Annealing temperatures used differed depending on 
the primer set used: 50°C for 16S rRNA primers, 60°C for nuc_qPCR primers. 
3.7. Plasmid standards 
3.7.1. Preparation of the p(16S) standard 
An aliquot of the p(16S) standard used was kindly donated by Dr Michael Cox (University of 
Birmingham). The plasmid standard used was a TOPO TA pCR2.1 vector containing the full length 
16S rRNA gene from the Vibrio natriegens strain DSMZ 759. It was used at a working 
concentration of 2x107 copies/µl. A plasmid map of the V. natriegens 16S rRNA gene in a TOPO 
TA pCR2.1 vector can be found in Appendix 9.2. 
The plasmid was transformed into DH5α E. coli cells by heat shock. A 50µl aliquot of chemically 
competent DH5α cells were taken from the -80°C freezer and defrosted on ice. Once defrosted, 5µl 
of the original p(16S) standard was added and left on ice for 30 minutes. The sample was then 
heat shocked in a 42°C water bath for 2 minutes, before being placed on ice for a further 5 
minutes. 750µl LB broth was then added, mixed briefly and then incubated at 37°C in a shaking 
incubator for an hour. After incubation, the sample was centrifuged for 1 minute at 12,000 x g. Most 
of the supernatant was removed, leaving ~100µl in which the pellet was then resuspended before 
being streaked onto a plate of LB agar containing ampicillin (100µg/ml) and incubated at 37°C for 
18 hours. After incubation, single colonies were taken, added to 5ml of LB broth and incubated at 
37°C for 18 hours. A stock of DH5α containing the p(16S) plasmid was produced by diluting this 
culture at a 1:1 ratio with 50% glycerol and frozen at -80°C. 
To produce a working stock, some DH5α cells containing the p(16S) plasmid were taken from the 
stock at -80°C and grown in LB broth at 37°C for 18 hours. The plasmid was recovered from this 
culture using a GeneJET Plasmid Miniprep Kit according to the manufacturer’s instructions. The 
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recovered plasmid was quantified using a NanoDrop spectrophotometer. To dilute the recovered 
plasmid to a working concentration of 2x107, the total length of the plasmid was calculated based 
on the plasmid length stated in the TOPO TA pCR2.1 user guide [43] (3931 base pairs) and the 
length of the inserted Vibrio natriegens DSMZ 759 16S rRNA gene (1465 base pairs). Copy 
number per µl was calculated using the online URI Genomics & Sequencing Center copy number 
calculator [44] and the sample diluted to give a final concentration of 2x107. 
3.7.2. Production of the p(nuc) standard 
The p(nuc) plasmid standard produced was a pCDF-Duet-1 vector containing the full length nuc 
gene from the Staphylococcus aureus strain JE2. The p(nuc) standard was used at a working 
concentration of 2x107 copies/µl. A plasmid map of the S. aureus nuc gene in a pCDF-Duet-1 
vector can be found in Appendix 9.3. 
The first stage in the production of a p(nuc) standard was to design suitable primers for the 
restriction digest of the nuc gene out of the S. aureus genome. Both primers were designed to 
contain a restriction site at the 5’ end and an ATAT repeat was also added at the 5’ end of each 
restriction site to increase the binding capability of the restriction enzymes to the sequences during 
the restriction digest (Figure 4). An EcoRI site was added to the forward primer and a KpnI site was 
added to the reverse primer. The total nuc amplicon length was 749bp including the primers, 
restriction sites and ATAT repeats, and can be found in Appendix 9.4. 
 
 
Figure 4 - Restriction digest primer design. Both primers were designed to contain a restriction site 





The vector used for the p(nuc) standard was pCDF-Duet-1. This vector was selected as it was not 
possible to use the TOPO-pCR-2.1 vector used for the p(16S) plasmid, and pCDF-Duet-1 is similar 
in size (TOPO-pCR-2.1 = 3931bp; pCDF-Duet-1 = 3781bp). The pCDF-Duet-1 plasmid used was 
kindly donated by John Shaw (University of Bristol). 
To isolate the nuc fragment, 1µl of genomic DNA extracted from the S. aureus strain JE2 using the 
Roche High Pure PCR Template Preparation Kit was used according to the manufacturer’s 
instructions. The 1µl of JE2 DNA was amplified by PCR using the RD_nuc_F_(EcoRI) and 
RD_nuc_R_(KpnI) primers. The PCR reaction had a total volume of 20µl, comprised of 10µl Kapa 
Hifi HotStart ReadyMix, 1µl of each primer, 1µl of the JE2 genomic DNA template and 7µl of PCR 
grade water. Two samples were run, along with a negative control which substituted the DNA 
template for PCR grade water. The conditions of this PCR reaction can be found in Table 7. 















Final Extension 72°C 300 (5 min) 1 
Final Store 10°C ∞ - 
Table 7 – PCR conditions used for isolation of nuc gene fragment during cloning procedure to 
produce p(nuc) plasmid standard. 
To check the amplified nuc fragment produced by PCR, the PCR products were run on a 1.5% 
agarose gel containing 0.1µl/ml SYBR-Safe gel stain. 5µl of each PCR product was loaded into 
respective wells and electrophoresis was carried out at 300mA, 90V for 30 minutes. This confirmed 
a fragment of the expected size in the template positive samples, which was absent in the negative 
sample. 
The remaining PCR product for the nuc positive samples was purified using a Zymo Genomic DNA 
clean and concentrator kit according to the manufacturer’s instructions. The product was eluted in 
15µl of the elution buffer provided in the kit, and DNA concentration of both samples quantified 
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using a NanoDrop Spectrophotometer (207.7 ng/µl and 211.1 ng/µl respectively). The purified nuc 
fragments were stored at -20° until required. 
To prepare the plasmid vector, 1µl of pCDF-Duet-1 purified plasmid (at 172.1 ng/µl) was added to 
50µl of competent DH5α cells in a microcentrifuge tube and mixed by gentle pipetting. The tubes 
were then left on ice for 30 minutes before being subjected to heat shock at 42°C for 2 minutes on 
a thermal block. After the heat shock, the tubes were placed back on ice for 3 minutes, then 700µl 
LB broth was added and the tubes were incubated at 37°C for 1 hour in a shaking incubator. After 
incubation, the tubes were centrifuged at 8,000 RPM for 5 minutes, the majority of the supernatant 
discarded and the pellet resuspended in the remaining ~100µl of supernatant before being plated 
out on LB agar plates containing 30µg/ml streptomycin to select for DH5α cells containing the 
pCDF-Duet-1 plasmid. Plates were incubated at 37°C for 18 hours, then a single colony was 
transferred to 5ml LB broth containing 30µg/ml streptomycin and incubated at 37°C for a further 18 
hours in a shaking incubator. After incubation, two 900µl aliquots were combined 1:1 with 50% 
glycerol and stored at -80°C. The plasmid was reclaimed from the remaining DH5α cells using a 
Thermo Scientific GeneJet plasmid miniprep kit according to the manufacturer’s instructions. The 
plasmid was eluted in 50µl PCR grade water and quantified using a NanoDrop Spectrophotometer 
(209.5 ng/µl). 
The pCDF-Duet-1 plasmid vector and nuc fragment were then cut via restriction digestion using 
EcoRI and KpnI restriction enzymes (Figure 5). First, the purified plasmid and nuc fragment were 
both diluted to 200ng/µl. Next, 10µl (2µg) of either pCDF-Duet-1 or the nuc fragment was 
combined with 1µl EcoRI-HF, 1µl KpnI-HF, 5µl CutSmart buffer and 33µl PCR grade water. As a 
control, two single digests were also carried out on pCDF-Duet-1 using EcoRI and KpnI 
respectively. Reagents were combined, mixed thoroughly and incubated at 37°C for 4 hours. After 
incubation, 5µl of each restriction digest product was run on a 1% agarose gel containing 0.04µl/ml 
Gel-Red stain for 1 hour at 300mA and 90V. 3µl of 1kb ladder, 3µl of 50bp ladder and 3µl of uncut 
pCDF-Duet-1 was also run for comparison. The remaining restriction digestion products were 




Figure 5 – Diagram of endonuclease activity of EcoRI and KpnI restriction enzymes at their 
sequence specific restriction sites. 
To ligate the cut nuc fragment into the cut pCDF-Duet-1 plasmid, the insert and plasmid were 
combined at a 3:1 (insert:plasmid) ratio. Following the restriction digest, the cut nuc fragment was 
699bp in length and at a concentration of 31.2ng/µl; the cut pCDF-Duet-1 plasmid was 3551bp in 
length and at a concentration of 25.0ng/µl. The ligation reaction contained 100ng of DNA and had 
a total volume of 10µl; this was comprised of 4µl of the cut pCDF-Duet-1 plasmid, 1.9µl of the cut 
nuc fragment, 1µl of NEB 10x buffer for T4 DNA ligase with 10mM ATP, 1µl of NEB T4 DNA ligase, 
and 2.1µl of PCR grade water. An insert negative reaction was also performed which substituted 
the 1.9µl of cut nuc fragment for PCR grade water. All reagents were combined in a PCR tube and 
left for 2 hours at room temperature. The result was a pCDF-Duet-1 plasmid vector containing the 
nuc insert, henceforth designated as p(nuc). The p(nuc) plasmid was transformed into DH5α cells 
via heat shock using the same method stated above for the transformation of pCDF-Duet-1 into 
DH5α cells; a stock was combined 1:1 with 50% glycerol and stored at -80°C. 
Successful ligation of the nuc insert into pCDF-Duet-1, and subsequent transformation of p(nuc) 
into DH5α cells was confirmed by colony PCR. 10 single colonies of DH5α containing p(nuc), and 
2 colonies of DH5α not containing the p(nuc) plasmid, were added to independent microcentrifuge 
tubes containing 20µl of PCR grade water and mixed by pipetting. For each colony mix, 3µl was 
added to a PCR tube and combined with 10µl GoTaq Green Mastermix, 1µl of each primer and 5µl 
of PCR grade water. The primers used were ACYCDuetUP1 which is specific to a sequence on the 
pCDF-Duet-1 plasmid, and RD_nuc_R_(KpnI) which is specific to the nuc insert. This ensured that 
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logarithmic amplification would only occur if the DH5α colony contained pCDF-Duet-1 with the nuc 
fragment inserted (the p(nuc) plasmid). The conditions of the PCR reaction used can be found in 
Table 8. To visualise the results by electrophoresis, 7.5µl of each PCR product was run on a 1% 
agarose gel containing 0.1µl/ml of SYBR-Safe gel stain against 3µl of a 1kb DNA ladder and 3µl of 
a 50bp DNA ladder. All 10 colonies of DH5α containing p(nuc) produced positive results, and both 
colonies of DH5α not containing the p(nuc) plasmid produced negative results. 















Final Extension 72°C 300 (5 min) 1 
Final Store 10°C ∞ - 
Table 8 – Conditions used for colony PCR to check presence of p(nuc) standard in DH5α cells 
following transformation by heat shock. 
To prepare the p(nuc) standard, the plasmid was extracted from the p(nuc) positive DH5α cells 
using a GeneJET plasmid miniprep kit according to the manufacturer’s instructions. The purified 
plasmid was eluted in 50µl of the elution buffer provided in the kit and quantified using a NanoDrop 
Spectrophotometer; the concentration of the p(nuc) plasmid was 199.1ng/µl. The purified plasmid 
was checked for the nuc insert by restriction digest using EcoRI and KpnI as above. Once 
confirmed, the remaining plasmid was diluted to 2x107 copies/µl. The p(nuc) plasmid was 4280bp 
in length and at a concentration of 199.1ng/µl; copy number per µl was determined as 4.31x1010 
using the online URI Genomics & Sequencing Center copy number calculator [44]. To dilute the 
plasmid to 2x107 copies/µl, 1µl of p(nuc) was added to 2.155ml of qPCR grade water. The p(nuc) 




3.8. Phase lock gel 
3.8.1. Production of phase lock gel 
Phase lock gel (PLG) was made by combining 850g of dimethylsiloxane-350 with 150g of 325-
mesh silicon dioxide, mixing well and leaving in a 37°C shaking incubator for a week to mix fully. 
Once mixed, the gel was sterilised by autoclaving at 121°C for 15 minutes. Directions for making 
PLG were found on the BiteSizeBio and PipetteJockey websites [45, 46]. This produced a gel 
equivalent to commercial ‘Phase Lock Gel: Heavy’ [47]. 
3.8.2. Phase lock gel standardisation experiment 
This experiment aimed to determine the ability of phase lock gel (PLG) to reduce the variability 
between results for identical samples processed using the BB+P/C DNA extraction procedure. 
Three biological repeats were performed, with three technical repeats per biological repeat. 
For each biological repeat, a 10ml liquid culture of S. aureus strain JE2 was produced as described 
previously, 6ml was taken to produce 6 aliquots of 1ml each; three of these were designated as the 
PLG-positive (PLG+) group, the remaining three were the PLG-negative (PLG –) group. 6 aliquots 
of 1ml TSB were also produced and three added to each group. 
This resulted in four sample types: 
• JE2 PLG + 
• JE2 PLG –  
• TSB PLG + 
• TSB PLG – 
 
All samples were subjected to the BB+P/C DNA extraction protocol in parallel. Following the 
extraction, DNA for each sample was resuspended in 60µl low-EDTA TE buffer and yield was 
quantified using a NanoDrop spectrophotometer. Three readings were taken per sample and an 




3.9. Extended serial dilution experiments: Limit of detection (LoD) 
These experiments aimed to determine the sensitivity of the BB+P/C DNA extraction and 
associated qPCR analysis for each primer set used. This was done by calculating the limit of 
detection (LoD) and independent experiments were carried out to determine the LoD of each 
primer set for: 
1. The qPCR analysis stage in isolation 
2. The BB+P/C DNA extraction and qPCR analysis stage combined 
To determine the LoD of the qPCR stage in isolation both plasmid standards, p(nuc) and p(16S) 
(each at 2x107 copies per µl), were combined with 5µl of qPCR grade water to dilute them to 1x107 
per µl. A seven-fold serial dilution was then performed by adding 1µl of each standard to 9µl of 
qPCR grade water in series to produce set of samples containing a range from 1x107 copies per µl 
to 1 copy per µl. Two samples of 2µl were taken from each dilution and analysed by qPCR using 
the respective primer set (16S rRNA or nuc_qPCR). Each qPCR run also included two non-
template control (NTC) samples containing 2µl qPCR grade water instead of the plasmid standard. 
To determine the LoD of the BB+P/C DNA extraction and qPCR analysis stages combined, a 10ml 
liquid culture of S. aureus strain JE2 was produced as described previously. A thirteen-fold serial 
dilution was performed by taking 1ml from each JE2 containing dilution and adding it to 9ml of 
TSB, producing a series from the neat culture (N) to 1x10-14. This range was chosen as it was 
expected to pass beyond a dilution of 1 CFU/ml. For each dilution, three 1ml aliquots were added 
to individual petri dishes and TSA at 37°C was added, mixed briefly and left to set. Plates were 
incubated as described previously and then colonies counted and an average taken for each 
dilution. For each dilution containing at least 1 CFU/ml (N to 1x10-9), three individual 1ml samples 
were processed using the BB+P/C DNA extraction method along with three blank samples of 1ml 
TSB. DNA resuspended in 60µl low-EDTA TE buffer and 2µl from each DNA extract was analysed 




3.10. Impact of pleural fluid on efficacy of BB+P/C DNA extraction and qPCR analysis 
3.10.1. Pleural fluid 
These experiments aimed to determine the impact of pleural fluid on the efficacy of the BB+P/C 
DNA extraction method. Clinical samples were collected by the Pleural Service at Southmead 
Hospital in Bristol as part of routine clinical care, ethical approval was through the North Bristol 
Pleural Database. The pleural fluid used in these experiments was obtained from a lymphoma 
patient who suffered pleural effusion, requiring pleurocentesis to remove the fluid via a pleural 
catheter. Excess fluid of ~65ml was collected and stored at -20°C. The following day it was 
transported on ice to the University of Bristol where it remained stored at -20°C until required. The 
pleural fluid was defrosted on ice for 45 minutes and 30ml was transferred to a fresh falcon tube 
and vortexed to homogenise the sample; this 30ml was then separated into six 5ml aliquots. Six 
5ml aliquots of PBS were also produced for these experiments as a non-pleural fluid control. 
3.10.2. BB+P/C and qPCR efficacy check – S. aureus spike in clinical samples 
A 10ml liquid culture of S. aureus strain JE2 was produced as described previously and a 9-fold 
serial dilution was performed by taking 1ml from each JE2 containing dilution and transferring it to 
9ml of TSB. 1ml from each dilution was plated out in triplicate and incubated as described 
previously. Following incubation the colonies were counted, an average CFU/ml was taken for 
each dilution and these averages were then used to estimate the CFU/ml of the neat liquid culture 
of JE2 (~1.83x109 CFU/ml). A 10µl spike of neat liquid culture (containing ~1.83x107 cells) was 
added to three of the six 5ml aliquots of pleural fluid and to three of the six 5ml aliquots of PBS to 
produce four sample types with three replicates each: 
• Pleural fluid + ~1.83x107 cells of JE2 
• Pleural fluid + TSB 
• PBS + ~1.83x107 cells of JE2 
• PBS + TSB 
All twelve samples were then processed using the BB+P/C DNA extraction; following the 
extraction, the DNA was resuspended in 60ul low-EDTA TE buffer. 
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To determine the impact of the pleural fluid on the BB+P/C DNA extraction and qPCR stages 
combined, all DNA extracts were analysed by qPCR using both the 16S rRNA primers and the 
nuc_qPCR primers as described above. A standard curve of each respective plasmid standard 
(p(16S) or p(nuc)) at dilutions of 2x107, 2x106 and 2x105 and a non-template control of qPCR grade 
water was also analysed in each qPCR run. 
3.10.3. qPCR stage only efficacy check – pleural fluid spike in p(16S) and p(nuc) samples 
To determine the impact of the pleural fluid on the qPCR analysis stage in isolation the plasmid 
standards, p(16S) and p(nuc), were analysed independently. The same method was used to 
analyse the impact of pleural fluid on qPCR analysis for each primer set. For each primer set, four 
samples containing 1µl of the relevant plasmid standard at 2x107 copies per µl were produced. 1µl 
of DNA from the un-spiked pleural fluid sample was added to two of these samples, and 1µl of 
qPCR grade water was added to the remaining two tubes. This produced four sample types: 
• Plasmid standard + pleural fluid derived DNA 
• Plasmid standard + qPCR grade water 
• qPCR grade water + pleural fluid derived DNA 
• qPCR grade water only 
All samples for each primer set were analysed by qPCR as described above and an average Cq 




4. Results 1 – Selection of DNA extraction method 
4.1. Comparison of MetaPolyzyme vs. lysostaphin for cellular lysis when using a kit. 
One of the DNA extraction methods used was the Roche High Pure PCR Template Preparation kit, 
these experiments were performed to determine if there is a difference in the DNA yield produced 
from identical samples of S. aureus when using MetaPolyzyme rather than lysostaphin. If there is 
no significant difference, MetaPolyzyme can replace lysostaphin for all future experiments in this 
project which use the Roche Kit. 
The Roche Kit instructions recommends the use of lysozyme for isolation of DNA from bacteria, 
however, to isolate DNA from S. aureus cells the enzyme lysostaphin is routinely substituted for 
the recommended lysozyme, as this is needed to break down their thick peptidoglycan cell wall. 
The aim of this project is to be able to isolate DNA from any microorganisms present in a sample, 
not just S. aureus, so it was necessary to replace the highly specific lysostaphin enzyme with a 
broad-spectrum multi-lytic enzyme mix, such as MetaPolyzyme which contains mutanolysin, 
achromopeptidase, lyticase, chitinase, lysostaphin and lysozyme. As lysostaphin is routinely used, 
but MetaPolyzyme is more appropriate for the objectives of this project, it was logical to directly 
compare the ability of each enzyme when used for the cellular lysis step during the Roche Kit DNA 
extraction protocol. This experiment aimed to determine whether MetaPolyzyme could be used 
instead of lysostaphin to produce an equivalent yield of DNA from the kit-based method. 
An overnight culture of S. aureus (JE2) was divided into 500µl samples and DNA was extracted 
from all samples using the Roche kit. Three biological repeats were performed, with three technical 
replicates per biological repeat. For each biological repeat, half of the samples were processed 
using lysostaphin (Lys+Kit) for cellular lysis, the other half were processed using MetaPolyzyme 
(Met+Kit). All samples were incubated at 37°C for 15 minutes after the addition of lytic enzymes. 
The extracted DNA was quantified using a NanoDrop spectrophotometer. Comparison of the 
amount of DNA extracted from each sample set showed no significant difference (P=0.223, two-
tailed, unpaired t-test). Mean quantities are shown in Figure 6 and can be found in Appendix 9.5. 
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Figure 6 – Mean quantities of DNA extracted from a JE2 culture using the Roche kit and either 
lysostaphin (Lys+Kit) or MetaPolyzyme (Met+Kit) for cellular lysis. Mean DNA quantity for Lys+Kit 
= 71.67ng/µl; mean DNA quantity for Met+Kit = 83.63ng/µl. DNA was quantified using a NanoDrop 
spectrophotometer. Error bars show standard error. A t-test showed no significant difference 
between groups: P = 0.223; T = 1.442; N = 6; df = 4. Raw data can be found in Appendix 9.5. 
To ensure that the S. aureus DNA extracted from these samples was of equivalent amounts, the 
extracts were amplified by PCR using the 16S rRNA primers to show an approximate quantity of 
total bacterial DNA and the nuc_Hoegh primers to show a rough quantity of staphylococcus 
specific DNA. The PCR product was then visualised by agarose gel electrophoresis (Figure 7). 
 
Figure 7 – Agarose gel to visualise PCR product amplified using 16S rRNA primers (bands 1-6) 
and nuc_Hoegh primers (bands 7-12) after DNA extraction against a 50bp ladder. Bands 1-3 and 
7-9 were from Met+Kit extractions; bands 4-6 and 10-12 were from Lys+Kit extractions. Image 
captured using GeneSys UV transilluminator. 
 1   2   3   4   5   6 
 7   8   9  10 11 12 
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All bands for each primer set were of a similar brightness, again showing that the DNA extracted 
was of similar quantities. As there was no significant difference in the quantity of S. aureus DNA 
extracted when using MetaPolyzyme rather than lysostaphin, all further kit-based extractions were 
performed using MetaPolyzyme with confidence that any S. aureus in the samples would be 
successfully lysed. 
4.2. Comparison of extraction ability with fresh vs. frozen samples 
One consideration for studies using pulmonary clinical samples is the condition in which they will 
be provided. This is important as sample conditions prior to laboratory processing may significantly 
influence the results obtained [48]. The aim of this experiment was to determine if there is a 
significant difference in yield when extracting DNA from fresh or frozen samples as these are the 
two conditions in which clinical samples may be provided. Three DNA extraction methods were 
used: the Roche Kit with MetaPolyzyme method (Met+Kit), and two non-kit-based methods. One 
where MetaPolyzyme is used for cellular lysis followed by the use of phenol/chloroform for 
purification of the sample and ethanol precipitation of the DNA (Met+P/C); and one where bead-
beating is used to mechanically lyse the cells, followed by phenol/chloroform purification and 
ethanol precipitation (BB+P/C). 
Freezing a sample is a significant change in environmental conditions for the microorganisms 
within the sample, species react to freezing in different ways which may cause alterations in the 
relative viable microbial composition of the sample [49]. It is advantageous to be able to freeze 
samples for storage, but only if they can still provide an accurate depiction of the patient’s 
microbiome; therefore, it is important to have a DNA extraction method which has as little 
difference between fresh and frozen samples as possible. All DNA extractions for each method 
were performed in parallel. In order to extract in parallel, frozen samples were from a different S. 
aureus (JE2) overnight culture to the fresh samples. Frozen samples were produced by dividing 
the overnight culture into 500µl samples and leaving at -20°C for 24 hours. For each extraction 
method, three fresh and three frozen biological repeats were processed, with three technical 
repeats for each biological replicate. Average DNA quantities from each method are shown in 




Figure 8 – Average quantities of DNA for each extraction method on either fresh or frozen cultures 
of JE2: Fresh Met+kit = 99.38ng/µl; Frozen Met+kit = 91.78ng/µl; Fresh BB+P/C = 192.83ng/µl; 
Frozen BB+P/C = 191.03ng/µl; Fresh Met+P/C = 203.87ng/µl; Frozen Met+P/C = 123.14ng/µl. 
DNA was quantified using a NanoDrop spectrophotometer. Error bars show standard error. T-tests 
(fresh vs frozen): N = 6; df = 4; no significant difference between fresh and frozen for Met+Kit (P = 
0.616; T = 0.543) or BB+P/C (P = 0.748; T = 0.345); very significant difference between fresh and 
frozen for Met+P/C (P = 0.005; T = 5.748). Raw data can be found in Appendix 9.6. 
The BB+P/C extraction method showed no significant difference between processing fresh and 
frozen samples (P=0.748, 2 tailed Students t-test), producing a relatively high yield in both sample 
types. The Met+Kit method also showed no significant difference between sample types (P=0.616, 
2 tailed Students t-test) but produced a far lower yield than the BB+P/C method. The Met+P/C 
method showed the greatest difference between fresh and frozen samples (P=0.005, 2 tailed 
Students t-test), producing a relatively high yield from the fresh samples, and a relatively low yield 
from the frozen samples. These results suggest that the BB+P/C method may produce the most 
accurate results if the state of each sample cannot be controlled.  
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4.3. Comparison of kit vs. phenol/chloroform DNA extraction methods on neat culture 
To examine the relative yields obtained by the kit and non-kit-based methods for the extraction of 
total genomic DNA from S. aureus, the Roche Kit with MetaPolyzyme method (Met+Kit) was 
directly compared with the two non-kit-based methods (Met+P/C and BB+P/C. Three biological 
repeats were performed, with three technical replicates for each biological repeat. All samples 
used were 500µl from a neat overnight culture of S. aureus (JE2) and for each biological repeat, all 
DNA extraction methods were performed on the same day in parallel. Extracted DNA was 
quantified using a NanoDrop spectrophotometer, mean quantities for each method are shown in 
Figure 9 and can be found in Appendix 9.7. 
   
Figure 9 – Mean quantities of DNA using each extraction method from the same culture of JE2. 
Mean DNA quantity for Met+kit = 83.63ng/µl; mean DNA quantity for BB+P/C = 262.73ng/µl; mean 
DNA quantity for Met+P/C = 130.01ng/µl. For each condition, 3 samples were measured in 
triplicate using a NanoDrop spectrophotometer. Error bars show standard error. Raw data can be 
found in Appendix 9.7. 
The BB+P/C method produced the highest yield, however also showed the greatest variance 
between samples. Both the Met+Kit and Met+P/C methods produced significantly lower yields from 
the same starting sample. However, there is a chance that the Met+Kit and Met+P/C methods 
were saturated by the relatively high number of cells in a neat sample and would be more effective 
at a lower dilution. It is important that the DNA extraction method is able to work effectively at lower 
dilutions as pulmonary samples typically have a low microbial load.  
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4.4. Comparison of DNA extraction methods on serially diluted culture 
Up to this point, relatively high quantities of S. aureus cells were used for the extractions (~1x108-
1x109 colony forming units (CFU)), but it is likely that the CFU in the clinical samples will be 
considerably lower. As the efficiency of the extraction methods may be affected by the abundance 
of the starting material, this experiment aimed to compare the sensitivity of each DNA extraction 
method on samples with lower bacterial loads. A serial dilution was performed on an overnight 
culture of S. aureus (JE2) from neat (N, between 1x108 and 1x109 CFU) to 1x10-2 (1 in 100 
dilution). These dilutions were then split into 500µl samples and three biological repeats were 
performed per dilution for each extraction method. Three technical repeats were performed for 
each biological repeat. Extracted DNA was quantified using a NanoDrop spectrophotometer. Mean 
quantities for each dilution and method are shown in Figure 10 and can be found in Appendix 9.8. 
  
Figure 10 – Mean quantities of DNA for each extraction method on samples at different dilutions 
(Neat, 1 in 10, and 1 in 100): Neat Met+kit = 99.38ng/µl; Neat BB+P/C = 192.83ng/µl; Neat 
Met+P/C = 203.87ng/µl; 1 in 10 Met+kit = 15.82ng/µl, 1 in 10 BB+P/C = 41.32ng/µl; 1 in 10 
met+P/C = 17.17ng/µl; 1 in 100 Met+kit = 8.48ng/µl; 1 in 100 BB+P/C = 11.64ng/µl; 1 in 100 
Met+P/C = 10.53ng/µl. For each condition, 3 samples were measured in triplicate using a 




In the neat samples, the Met+P/C method produced the highest yield (204ng/µl), followed by the 
BB+P/C method (193ng/µl), and the Met+Kit method produced the lowest yield 99ng/µl by a 
significant margin. The DNA quantities significantly decreased between the neat and 1x10-1 (1 in 
10) dilution as expected, however the sensitivity of the NanoDrop was not high enough to provide 
an accurate quantification of the DNA at lower dilutions. To approximately visualise the DNA 
quantities, all samples were amplified with the 16S rRNA and nuc_Hoegh primers in separate PCR 
reactions and the products were subject to agarose gel electrophoresis. 
PCR and agarose gel electrophoresis showed a result for all samples when run with the 
nuc_Hoegh primers (Figure 11), with the BB+P/C samples significantly brighter at the 1x10-1 and 
1x10-2 dilutions. For PCR with 16S rRNA primers (Figure 12) all bands were fainter, suggesting a 
less efficient PCR cycle; no product was seen at 1x10-2, but again the BB+P/C samples were 
brighter at 1x10-1. 
       
   = Met+Kit               =  Met+P/C               = BB+P/C 
     1   2   3   4   5   6   7   8   9  
                                10 11 12  13 14 15 16 17 18 19 20  21 22  23 24  25 26 27   
A     B C 
(nuc) 
Figure 11 – Agarose gels (A, B, C) to visualise DNA extracted from serial dilution samples (Neat,     
1 in 10, and 1 in 100) and amplified with nuc_Hoegh primers. (Order of bands: Neat samples = 
Met+Kit (1, 2, 3), Met+P/C (4, 5, 6) and BB+P/C (7, 8, 9). 1 in 10 samples = Met+Kit (10, 11, 12), 
Met+P/C (13, 14, 15), BB+P/C (16, 17, 18). 1 in 100 samples = Met+Kit (19, 20, 21), Met+P/C = 
(22, 23, 24), BB+P/C = (25, 26, 27)). Image captured using GeneSys UV transilluminator. 
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As traditional PCR did not have a high enough sensitivity to determine the low quantities of DNA, 
qPCR was used to assess the relative quantities between samples. DNA from all samples was 
included in the same qPCR run with 16S rRNA primers. The mean quantitation cycle (Cq) values 
for each extraction method at each dilution are shown in Table 9 and Figure 13, raw cq values can 
be found in Appendix 9.9. The p(16S) plasmid standard containing the 16S rRNA gene from Vibrio 
natriegens at a known copy number (2x107) was included to give an approximate quantification of 
the amount of DNA in each sample and the expected change in Cq for each dilution. 
 Avg. Cq 
 Neat 1 in 10 1 in 100 
Met+Kit 15.67 23.25 28.86 
BB+P/C 13.56 18.45 26.13 
Met+P/C 19.42 25.59 30.00 
p(16S) 13.30 17.40 21.68 
Water (NTC) 30.36 
Table 9 – Data for comparison of methods at neat, 1 in 10, and 1 in 100 dilutions by qPCR using 
16S rRNA primers. Data visually represented in Figure 13; raw data in Appendix 9.9. 
     1   2   3   4   5    6   7   8   9                                  10 11 12 13 14 15 16 17 
 18 19 20  21 22  23 24  25  26  27 
   = Met+Kit               =  Met+P/C               = BB+P/C 
B A C 
(16S) 
Figure 12 – Agarose gels (A, B, C) to visualise DNA extracted from serial dilution samples (Neat,   
1 in 10, and 1 in 100) and amplified with 16S rRNA primers. (Order of bands: Neat samples = 
Met+Kit (1, 2, 3), Met+P/C (4, 5, 6) and BB+P/C (7, 8, 9). 1 in 10 samples = Met+Kit (10, 11, 12), 
Met+P/C (13, 14, 15), BB+P/C (16, 17, 18). 1 in 100 samples = Met+Kit (19, 20, 21), Met+P/C = 
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Figure 13 – Cq values from qPCR using 16S primers on DNA from each extraction method at 
different dilutions (Neat, 1 in 10, and 1 in 100) against the same dilutions of the p(16S) plasmid 
standard and a non-template water control. Error bars show standard error. 3 technical repeats 
were run for each dilution for all extraction methods. Raw Cq values can be found in Appendix 9.9. 
Comparison of the Cq values for each extraction showed that the BB+P/C method was able to 
extract a higher yield than either the Met+Kit or Met+P/C methods at all dilutions. This led to the 
selection of the BB+P/C method as the most effective DNA extraction method of the three 
compared in this study.  
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5. Results 2 – Development of BB+P/C extraction method 
5.1. Phase Lock Gel standardisation experiment 
One of the stages in the BB+P/C extraction protocol requires the aqueous phase to be separated 
from the organic phase below. This stage is reliant on visual determination of when the total 
aqueous layer has been isolated, creating a potential source of variability due to human error. An 
error at this stage may lead to loss of DNA through some of the aqueous phase not being isolated 
and subsequently discarded alongside the organic phase, or may lead to protein contamination of 
the sample by interrupting the interphase boundary between the aqueous and organic phases. The 
original protocol for the BB+P/C method which was provided by Dr Michael Cox (University of 
Birmingham) contained a note recommending the use of Phase Lock Gel to clearly separate the 
aqueous and organic phases, removing the possibility for human inconsistency to impact the 
results obtained. Phase lock gel works by producing a barrier layer between the organic and 
aqueous phases, preventing cross contamination from the organic phase into the aqueous, and 
removing the human variability factor when isolating the aqueous phase. 
To investigate whether phase lock gel would be able to reduce the variability of the BB+P/C DNA 
extraction method, a liquid culture of S. aureus strain JE2 was produced and divided into two 
sample groups. Each group of samples was subjected to the BB+P/C DNA extraction in parallel, 
with phase lock gel being used only for the first sample group. Two blank sample sets of TSB were 
also processed, one with phase lock gel, the other without. This served to show whether the phase 
lock gel itself would impact the results produced. Three biological repeats were performed, with 
three technical repeats for each biological repeat. All samples were processed, and the DNA yields 
of the resulting extracts were quantified using a NanoDrop Spectrophotometer. Results from this 












PLG - 1425.01 396.15 
PLG + 2014.81 115.81 
Blank 
(TSB) 
PLG - 19.54 4.12 
PLG + 18.82 4.57 
Table 10 – Average DNA yields from phase log gel (PLG) tests to determine the effect of PLG on 
the variability of samples. DNA was quantified using a NanoDrop spectrophotometer. Data visually 
represented in Figure 14. Raw data can be found in Appendix 9.10.  
 
Figure 14 – Average DNA yields from phase log gel (PLG) tests to determine the effect of PLG on 
the variability of samples. For each condition, 3 samples were measured in triplicate using a 
NanoDrop spectrophotometer. Error bars show standard deviation. Raw data can be found in 
Appendix 9.10.  
For each sample in this experiment, three readings were taken on a NanoDrop spectrophotometer 
and an average reading was produced for each sample (1 to 12), as well as an average quantity 
for each sample type (JE2, JE2+PLG, TSB and TSB+JE2). The standard deviation was calculated 
from the raw data readings to show the total variation in each sample type. This experiment 
showed that when samples were processed using phase lock gel, the variability of the samples 
was significantly reduced. The JE2 samples processed without phase lock gel showed a standard 
deviation of 396.15ng/µl between samples, compared to 115.81ng/µl in the JE2+PLG samples; 
almost a 3.5-fold difference between sample types. 
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Furthermore, both the TSB blank samples showed comparable results with no significant 
difference between the TSB and TSB+PLG sample types (P=0.729 in a 2-tailed Students t-test), 
demonstrating that the presence of phase lock gel does not contaminate the sample and artificially 
increase the yield detected. Interestingly, the presence of phase lock gel caused a significant 
increase in the amount of DNA obtained from the samples of JE2 (P=0.00186 in a 2-tailed 
Students t-test with unequal variance). This increase was not observed in the TSB+PLG blank 
samples when compared to the TSB samples not containing PLG. Therefore, it can be assumed 
that the increase in DNA obtained is not due to contamination from the phase lock gel itself, or 
from an interference from residual phase lock gel on the A260/280 reading of the 
spectrophotometer used to quantify DNA yield. Aside from the S. aureus JE2 culture used, there 
was no other source of DNA in the experiment, suggesting that the yields produced by the 
JE2+PLG samples more closely reflect the true yield of the sample and that there is a significant 
loss of yield (on average) in the samples processed without using phase lock gel. Closer scrutiny 
of the samples supports this theory as sample 1 (JE2 without PLG) is comparable to the JE2+PLG 
samples, but the other two replicate JE2 samples processed without phase lock gel show a 
reduced DNA yield. This may be due to either not isolating the entirety of the aqueous phase, 
thereby losing some of the DNA in the samples during processing, or it may be due to 
contamination of the sample from material in either the interphase layer or organic phase which 
could interfere with the A260/280 reading from the NanoDrop spectrophotometer used to quantify 
each sample. 
 
5.2. Production of nuc_qPCR primers and p(nuc) standard 
Prior to performing the extended serial dilution experiments to determine the limit of detection 
(LoD) of the BB+P/C DNA extraction method, it was necessary to make the protocol more specific 
for detecting S. aureus from complex samples. This included producing a set of primers specific to 
the nuc gene which wouldn’t produce a product with DNA templates from any other 
microorganisms (nuc_qPCR primers), and also included the production of a plasmid standard 
(p(nuc)) in order to determine the LoD of the qPCR analysis stage with the nuc primers. 
39 
 
New primers for the nuc gene were required for extraction from complex samples as the 
nuc_Hoegh set had been shown to produce a product with Streptococcus pneumoniae strain d39 
in an experiment unrelated to this project. Until this point of the project, the nuc_Hoegh primers 
fulfilled the requirements necessary of the nuc primer set as all experiments had been performed 
on pure cultures of S. aureus, however the nuc_Hoegh primers would not be suitable for use on 
complex samples of unknown microbial compositions. 
The first stage in producing the new nuc_qPCR primers was to perform multiple sequence 
alignment from a broad selection of S. aureus strains to determine a consensus sequence for the 
nuc gene. Sequences for the nuc gene were taken for 31 strains of S. aureus (Table 11); the gene 
was inverted in several strains so the reverse complement for these strains was produced using an 
online sequence converter [50]. Multiple sequence alignment was then performed using MultAlin 
[51] producing a consensus sequence for the S. aureus nuc gene (Figure 15). The most 
homologous region of the nuc gene consensus sequence was then selected as a target sequence 
for the nuc_qPCR primers (Table 12).  



































Table 11 – List of 31 representative strains of S. aureus used for multiple sequence alignment of 
nuc gene as part of the production of nuc_qPCR primers. List originally produced by AureoWiki 
[52] to produce a pan-genome for S. aureus. 
 















Figure 15 – Full consensus sequence of nuc gene produced by multiple sequence alignment of 31 
representative strains of S. aureus. Red text denotes common SNPs. 
 
Most homologous region of 









Table 12 - The most homologous region of the nuc gene, determined by multiple sequence 
alignment of the nuc gene from 31 representative strains of S. aureus. Primers were produced to 
amplify within this homologous region in order to attain the highest level of coverage of S. aureus 





The specificity of the primers produced (nuc_qPCR_F and nuc_qPCR_R) was assessed using the 
NCBI Primer BLAST tool [53], this found the primers to only have an expected specificity to the S. 
aureus nuc gene. As the previous nuc primer set (nuc_Hoegh) had produced a product with S. 
pneumoniae strain d39, a specificity test was performed including 2 genomic DNA (gDNA) 
templates from S. aureus strain JE2, 2 from S. pnumoniae strain d39, and 2 non-template controls 
of qPCR-grade water. All samples were analysed by qPCR using the nuc_qPCR primers. A 
product was produced with the JE2 template, but not with the d39 or water samples (Figure 16 and 
Table 13). 



















Figure 16 – Results from nuc_qPCR primers specificity test. qPCR performed on samples 
containing template DNA from S. aureus JE2, S. pneumoniae d39 or water non-template control 
using nuc_qPCR primers. Error bars show standard error. For each condition, N = 2. Data shown 




A B Avg. 
JE2 9.34067 8.92179 9.13 
d39 -1 -1 0.00 
NTC (water) -1 -1 0.00 
Table 13 – Data from nuc_qPCR primers specificity test. qPCR performed on samples containing 
template DNA from S. aureus JE2, S. pneumoniae d39 or water non-template control using 
nuc_qPCR primers. Demonstrated specificity of primers for S. aureus. 
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To determine the efficiency of the nuc_qPCR primers, a 1 in 5 serial dilution was performed on JE2 
gDNA from 62.5ng/µl to 0.5ng/µl; 2 technical replicates per dilution were used for qPCR as well as 
2 non-template control samples (Table 14a). From the Cq values acquired, it was possible to 
calculate the efficiency of the primer set as 94.3% with an R2 value of 0.9994 (Table 14b). 
Sample 
(JE2 DNA) 
Cq Value  Analysis 
A B Avg.  Slope -3.466575976 
62.5ng 11.16032 10.77660 10.97  R
2 0.9994 
12.5ng 13.51483 13.44775 13.48  Efficiency (%) 94.30 
2.5ng 17.32561 14.60272 15.96    
0.5ng 17.31467 19.12055 18.22    
NTC (water) -1 -1 0.00    
Table 14 – Efficiency of nuc_qPCR primers. A) Cq values from qPCR on a serial dilution series of 
S. aureus JE2 genomic DNA and water non-template control. B) Determined efficiency of 
nuc_qPCR primer set based on Cq values obtained. R2 value indicates accuracy of efficiency 
calculation (optimal value: 1); Slope is used to determine efficiency value (optimal value: -3.3). 
 
A new plasmid standard was required for use with the nuc primer set as the LoD for the method is 
likely to differ depending on the primer set used, and therefore each primer set must have its own 
complimentary plasmid standard. The p(nuc) standard consists of the full length nuc gene from S. 
aureus in a pCDF-Duet-1 vector, diluted to a known copy number of 2x107 copies per µl. It was 
produced by isolating the nuc gene from S. aureus strain JE2 and inserting it into the plasmid by 
restriction digestion. The p(nuc) plasmid was then transformed into DH5α E. coli cells, checked by 
colony PCR and cultured in liquid broth. 
The p(nuc) plasmid was then extracted using a plasmid miniprep kit and diluted to 2x107 copies 
per µl. To monitor the success of the cloning procedure, the DNA products were inspected by 
agarose gel electrophoresis at several checkpoints. These checks were performed following 
isolation of the nuc gene (Figure 17), following the restriction digest of the nuc fragment into the 
pCDF-Duet-1 plasmid vector (Figure 18), and following the transformation of the p(nuc) plasmid 




Figure 17 – Agarose gel to check nuc fragment amplified by PCR. Electrophoresis conditions: 
300mA, 90V, 30m. 1.5% agarose gel containing 0.1µl/ml SYBR-Safe gel stain. Total volume of 5µl 
loaded per well. Order of wells: 1kb ladder, nuc fragment template positive 1 (nuc +ve 1), nuc 
fragment template positive 2 (nuc +ve 2), nuc fragment template negative (nuc -ve), 50bp ladder. 
Gel confirmed the presence of a fragment of the expected size in the template positive samples 
(nuc +ve 1 and nuc +ve 2), which was absent in the negative sample (nuc -ve). 
 
Figure 18 – Agarose gel to check restriction digest of pCDF-Duet-1 plasmid vector and nuc 
fragment using EcoRI and KpnI. Electrophoresis conditions: 300mA, 90V, 60m. 1% agarose gel 
containing 0.04µl/ml Gel-Red stain. Total volume of 5µl loaded per well. Order of wells: 1kb ladder, 
nuc gene double digest (EcoRI + KpnI), pCDF-Duet-1 double digest (EcoRI + KpnI), pCDF-Duet-1 
single digest (EcoRI), pCDF-Duet-1 single digest (KpnI), pCDF-Duet-1 uncut plasmid, 50bp ladder. 
This confirmed that the restriction digest was successful, the nuc double digest showed a band at 
the expected size, and all plasmid digests showed bands as expected relative to each other and 





Figure 19 – Agarose gel of colony PCR product to check transformation of p(nuc) (pCDF-Duet-1 
plasmid vector and nuc fragment) into DH5α cells. Electrophoresis conditions: 300mA, 90V, 60m. 
1% agarose gel containing 0.1µl/ml SYBR-Safe gel stain. Total volume of 7.5µl loaded per well. 
Order of wells: 1kb ladder, p(nuc) positive DH5α 1 to 10, p(nuc) negative DH5α 1 to 2, 50bp 
ladder. This confirmed that all 10 positive colonies of DH5α did contain p(nuc), and that both 
negative colonies of DH5α did not contain p(nuc). The negative colonies produced no bands as the 
forward primer used for PCR (ACYCDuetUP1) was specific to the plasmid and the reverse primer 
(RD_nuc_R_(KpnI)) was specific to the nuc insert. Therefore, only colonies containing the nuc 
gene in the plasmid would produce a result. 
 
5.3. Extended serial dilution experiments to determine limit of detection (LoD) 
5.3.1. LoD of qPCR analysis stage 
The serial dilution comparison previously carried out (Section 4.4; neat to 1x10-2) was enough to 
see a difference between the methods and determine which one had the highest sensitivity of the 
three. However, in order to assess the extent of the most effective method’s sensitivity, a further 
serial dilution experiment including samples ranging from a neat culture to 1 CFU/ml was required. 
It would not have been appropriate to perform this extended serial dilution with all three methods in 
parallel as this would have been highly laborious, decreasing the quality of the results obtained. 
As the BB+P/C method had been shown to be the most effective method at extracting microbial 
DNA from low yield samples, it was necessary to find the limit of detection (LoD) of this method 
with both the nuc primers and the 16S rRNA primers. The BB+P/C method consists of two stages 
which may affect LoD: the DNA extraction stage, and the qPCR analysis stage. As qPCR is a 
notoriously sensitive molecular detection technique it was expected that if the LoD was impaired by 
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this method, most of the impact would be from the DNA extraction stage itself. As investigation of 
the DNA extraction stage is reliant on qPCR analysis, the qPCR stage was investigated first in 
isolation. 
To find the baseline LoD of the qPCR analysis stage, the LoD for the p(nuc) and p(16S) standards 
was determined through analysis in independent qPCR reactions. Each standard at 2x107 
copies/µl was first diluted to 1x107 copies/µl, then a 7-fold, 1 in 10 serial dilution was performed to 
produce samples containing a range from 10,000,000 copies per µl to 1 copy per µl. From each of 
these samples, two samples of 2µl each were then analysed by qPCR. In each qPCR run, two 2µl 
water non-template controls (NTC’s) were also run alongside the standards; these were identical to 
the other samples except they contained 2µl of qPCR grade water rather than a DNA template. 







Avg. Cq value 
p(nuc) p(16S) 
N 2 x 107 14.25 13.73 
1 x 10-1 2 x 106 17.4 17.54 
1 x 10-2 2 x 105 21.18 21.05 
1 x 10-3 2 x 104 23.99 23.97 
1 x 10-4 2 x 103 26.87 27.61 
1 x 10-5 200  29.07 29.83 
1 x 10-6 20 31.19 31.06 
1 x 10-7 2 0 31.86 
Water NTC 0 0 31.93 
Table 15 – Average Cq values of serial dilution samples of plasmid standards, p(nuc) and p(16S), 
analysed by qPCR to find the LoD of the qPCR analysis stage in isolation. 2µl of each sample at 
1x10(n) was used per qPCR reaction. Visually represented in Figure 20. Raw data in Appendix 
9.11.1.  
Through comparison of the Cq values produced for each serially diluted standard, it was possible 
to calculate the LoD of the qPCR analysis stage for each primer set. The cut-off point used to 
determine a significant difference between a sample and the water NTC was 1Cq + 2 standard 
deviations (1Cq+2SD). The nuc primers did not produce a detectable product in the water NTC or 
the sample containing 2 copies of p(nuc) in the qPCR run, so the LoD when using the nuc_qPCR 
primers and 40 PCR cycles was determined as the lowest dilution to produce a result. This was 20 
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copies of the nuc gene (Figure 20a). The LoD ascertained for qPCR analysis with the 16S rRNA 
primers was determined by taking the first dilution to not be within 1Cq+2SD of the water NTC, this 
was 200 copies of the 16S rRNA gene (Figure 20b). Therefore, the qPCR analysis stage was 
determined to have a limit of detection of 20 copies with the Staphylococcus aureus specific nuc 
primers and 200 copies with the universal 16S rRNA primers; these LoD scores for the qPCR 
stage alone were used as a baseline for evaluating the LoD of the DNA extraction and qPCR 
































































































Figure 20 – Graphs to show avg Cq values from qPCR analysis of a) p(nuc) and b) p(16S) 
standard serial dilutions to calculate LoD of qPCR stage. Hashed lines denote samples not 
significantly different to the water non-template control (i.e. avg. Cq of sample is within 1Cq+2SD 
of NTC). Limit of detection determined as the last sample to produce an average Cq statistically 
distinct from the average Cq of the NTC. A) avg. qPCR values for serially diluted p(nuc) standard; 
B) avg. qPCR values for serially diluted p(16S) standard. Error bars show standard error. Summary 





5.3.2. LoD of BB+P/C DNA extraction and qPCR analysis stages combined 
To determine the LoD of the combined extraction and qPCR analysis stages, an extended 1 in 10 
serial dilution was carried out on an overnight culture of S. aureus JE2. The dilution series was 
performed from a neat culture down to 1x10-14 to ensure it would extend past a cell count of 1 
CFU/ml. DNA was extracted from each of these samples in triplicate, alongside three blank 
samples of TSB using the BB+P/C method. Following the extractions, samples were compared by 
qPCR analysis in order to determine the LoD for each primer set under the conditions used: each 
sample had a starting volume of 1ml, DNA was resuspended in 60µl after extraction, and 2µl of 
each DNA extract was used for qPCR analysis. 
By the 1x10-9 dilution of the serial dilution series, the sample contained approximately 1 CFU/ml 
(Table 16, raw data in Appendix 9.11.2). Scaling this up across the dilution series indicates the 
neat starting culture of JE2 contained approximately 1x109 CFU/ml. In a clinical setting, a positive 
BAL sample is determined as one which contains more than 1x104 CFU/ml [17], this would equate 
to the 1x10-5 dilution in this experiment. 
Sample 
Avg. CFU/ml Estimated CFU/ml 
Number Dilution 
1 Neat - ~1,000,000,000 (1 x 109) 
2 1 x 10-1 - ~100,000,000 (1 x 108) 
3 1 x 10-2 - ~10,000,000 (1 x 107) 
4 1 x 10-3 - ~1,000,000 (1 x 106) 
5 1 x 10-4 - ~100,000 (1 x 105) 
6 1 x 10-5 - ~10,000 (1 x 104) 
7 1 x 10-6 1032.00 ~1,000 (1 x 103) 
8 1 x 10-7 119.00 ~100 (1 x 102) 
9 1 x 10-8 10.00 ~10  
10 1 x 10-9 0.33 ~1 
B Blank (TSB) 0.00 0 
Table 16 – Average CFU/ml plate counts from a serial dilution of JE2 liquid culture used for LoD 
experiments. Approximate CFU/ml counts for later dilutions (1x10-6 to 1x10-8) were extrapolated to 





For each dilution containing at least 1 CFU/ml (samples 1 to 10; neat culture to the 1x10-9 dilution), 
total DNA was extracted from three individual 1ml samples using the BB+P/C method. Three blank 
samples of TSB were also put through the extraction procedure parallel to the serial dilution 
samples. After the extraction, DNA was resuspended in 60µl of low-EDTA TE buffer. 2µl from each 
60µl DNA extract was analysed via qPCR using both generic 16S rRNA primers, and 
Staphylococcus aureus specific nuc primers. Comparison of the Cq values produced by serially 
diluted samples against the blank TSB sample would show the limit of detection (LoD) of the 
extraction method and qPCR analysis using both sets of primers. Ideally, the standards would 
have also been run alongside the DNA extracts from samples containing JE2, however this was 
not possible due to space constraints on the thermocycler. 
The qPCR analysis of the DNA extracts produced a series of Cq values which were used to 
calculate the LoD of the method for each primer set. This was achieved by selecting the last 
dilution before the point at which the average Cq value from the DNA extract would be within 1 Cq 
and 2 standard deviations (1Cq+2SD) from either the blank sample or non-template control (NTC). 
The LoD of the BB+P/C DNA extraction method and qPCR analysis combined was found to be 
1x103  CFU/ml with nuc primers (Figure 21a), and 1x104 CFU/ml with 16S rRNA primers (Figure 
21b) under the conditions stated. These LoD cut-off points indicate the lowest number of cells in 
1ml of a sample which can be extracted using the BB+P/C method and reliably detected through 
qPCR analysis, producing a result which is clearly distinct from an unspiked control sample with 
each primer set. Average Cq values are shown in Table 17 and raw Cq values can be found in 


















































BB+P/C + qPCR LoD: extracted JE2 (nuc)


























































BB+P/C + qPCR LoD: extracted JE2 (16S)












Figure 21 – graphs to show avg Cq values used to calculate LoD of BB+P/C DNA extraction + 
qPCR analysis. DNA extracts used for qPCR were from a serial dilution series on S. aureus JE2. 
Hashed lines denote samples not significantly different to the blank (TSB) control (i.e. avg. Cq of 
sample is within 1Cq+2SD of blank (TSB) control). Limit of detection determined as the last sample 
to produce an average Cq statistically distinct from the average Cq of the blank (TSB). A) avg. 
qPCR values using nuc_qPCR primers; B) avg. qPCR values using 16S rRNA primers. Error bars 







  Avg. Cq value 
  nuc 16S 
CFU/ml 
of JE2 
100,000,000 11.30 10.32 
10,000,000 15.95 15.21 
1,000,000 21.29 24.09 
100,000 25.19 28.02 
10,000 25.53 29.00 
1,000 27.69 30.85 
100 28.02 31.07 
10 27.16 29.51 
1 27.19 29.89 
Blank (TSB) 29.10 34.11 
NTC (Water) 0.00 30.26 
Table 17 – Average Cq values from qPCR to determine the LoD of BB+P/C and qPCR stages combined. 
qPCR performed using both 16S rRNA primers and nuc primers. Visually represented in Figure 21. Raw 
data in Appendix 9.11.3.  
 
  Limit of detection (LoD) 
qPCR analysis only 
p(nuc) standard 20 copies 
p(16S) standard 200 copies 
DNA extraction + qPCR analysis 
JE2 (nuc primers) 1 x 103 CFU/ml 
JE2 (16S rRNA primers) 1 x 104 CFU/ml 
Table 18 – LoD calculated for each primer set (nuc_qPCR and 16S rRNA) for either qPCR 
analysis stage only, or for DNA extraction and qPCR analysis stages combined. 
 
It is important to note that the LoD figures for the extraction and qPCR analysis combined are 
based on Cq results from qPCR runs utilising only 2µl of the total 60µl DNA extract for each 
sample. The 60µl extract theoretically contains the total quantity of DNA present in the original 1ml 
sample. Loading the full 60µl into the qPCR reaction would overload the qPCR run preventing the 
acquisition of accurate results; therefore, 2µl was used in each qPCR run and the Cq values 
produced are representative of only 1/30th of the initial 1ml sample. For this project, an LoD has 
been calculated based on the input number of cells for each sample to show the lowest number of 
cells this method is able detect from 1ml of a sample when DNA is resuspended in 60µl and 2µl of 
this is then used for qPCR analysis. Further considerations regarding the quantity of DNA 
represented in the qPCR analysis stage are explored in more detail in the discussion section. 
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5.4. DNA extractions from spiked clinical samples of pleural fluid 
5.4.1. Pleural fluid samples 
Once the capabilities of the BB+P/C DNA extraction protocol had been established on mock-
samples of a single organism and the LoD was found to be acceptable for the intended uses of this 
method, it was important to ensure the efficacy would not be impaired when used on complex 
clinical samples. For these experiments, 30ml of pleural fluid was obtained from a lymphoma 
patient at Southmead Hospital in Bristol. This patient suffered pleural effusion requiring 
pleurocentesis, the fluid collected was frozen and transported to the University of Bristol where it 
was stored at -20°C until required. 
The pleural fluid was defrosted on ice for 45m, then 30ml was isolated and vortexed to 
homogenise any clumps of cells before being separated into six individual 5ml samples. A liquid 
culture of S. aureus strain JE2 was grown overnight and used as the neat culture for a serial 
dilution series; the neat culture was shown to be at 1.83x109 CFU/ml by culturing spread plates of 




plate 1 plate 2 plate 3 
Neat TNTC TNTC TNTC ~1.83 x 10^9 
1 x 10-1 TNTC TNTC TNTC ~1.83 x 10^8 
1 x 10-2 TNTC TNTC TNTC ~1.83 x 10^7 
1 x 10-3 TNTC TNTC TNTC ~1.83 x 10^6 
1 x 10-4 TNTC TNTC TNTC ~1.83 x 10^5 
1 x 10-5 TNTC TNTC TNTC ~1.83 x 10^4 
1 x 10-6 1752 1792 1880 1808.00 
1 x 10-7 168 212 203 194.33 
1 x 10-8 22 16 14 17.33 
1 x 10-9 0 3 1 1.33 
1 x 10-10 0 0 0 0.00 
Table 19 – Plate count values of colony forming units per ml (CFU/ml) from serial dilution series of 
S. aureus JE2 liquid culture. Average CFU/ml for samples from 1x105 to the neat sample are 
predicted values which were extrapolated from the values counted at lower levels of the dilution 




Half of the six 5ml samples of pleural fluid were then spiked with 10µl of the neat JE2 liquid culture, 
an equivalent of 1.83x107 cells per sample; 10µl of sterile TSB was added to the remaining pleural 
fluid samples. Alongside the pleural fluid samples, six control samples of phosphate buffered saline 
(PBS) were also used, half of which were also spiked with 1.83x107 cells of JE2 and half with 10µl 
of sterile TSB. The 4 sample types produced are summarised in Table 20. All samples were put 
through the BB+P/C double extraction procedure, producing 60µl of DNA extract for each sample 
which could be analysed by qPCR using two primer sets: one targeting the Staphylococcus aureus 
specific nuc gene, and one targeting the V3-V4 region of the 16S rRNA gene which is universal to 
all bacteria. There are two stages during the sample processing where the quality of results could 
be impaired, these are either during the extraction itself, or during the analysis by qPCR.  As the 
extraction stage is reliant on qPCR for analysis of results, it was logical to investigate the impacts 
of using a complex clinical sample on the qPCR stage in isolation before investigating the efficacy 










Pleural fluid (+) 
or PBS (-) 
- - + + 
10µl of S. aureus (JE2) (+) 
or 10µl TSB (-) 
- + - + 
Table 20 – Summary of sample types produced for pleural fluid spiking experiments. All samples 
were used for JE2 spike experiments to determine the efficacy of the BB+P/C DNA extraction 
method when extracting from a complex clinical sample. Sample 3 was also used for qPCR 
inhibitor checks analysing the impact of PF on the qPCR analysis stage. The 10µl of JE2 added to 
samples 2 and 4 contained ~1.83x107 cells. 
 
5.4.2. qPCR inhibition test: nuc_qPCR primers 
The robustness of the qPCR stage when using a template derived from a clinical sample was 
examined through a set of spike-in experiments for each primer set. The clinical samples of pleural 
fluid were likely to contain a background level of microorganisms which would produce a product 
with the 16S rRNA primers, so the Staphylococcus aureus specific nuc primers were tested first. 
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Four samples were produced of the p(nuc) standard at 2x107 copies per µl; these were then 
separated into two individual sets. Each set also contained two non-template control samples of 
qPCR grade water. To the first set, 1µl of DNA extract from the un-spiked pleural fluid sample 
(PF+TSB) was added to each sample. To the second set, 1µl of qPCR grade water was added. 
qPCR was then performed on two technical repeats for each sample (Figure 22; raw data in 
Appendix 9.12.1). 
If present, any PCR inhibitors in the pleural fluid DNA extract would impact the acquisition of 
accurate and reliable results through qPCR analysis on the samples containing DNA derived from 
the clinical pleural fluid samples. Therefore, if the samples containing pleural fluid produce an 
equivalent Cq value to the samples without pleural fluid, it can be assumed that any inhibitors 
present do not have a significant impact on the results from this qPCR run. However, this does not 
prove a definitive absence of any inhibitors and this must be taken into consideration if DNA 
extracts in future studies are used for any further downstream functions, such as sequencing. 
 
 
Figure 22 – Results from qPCR test to determine impact of pleural fluid on the qPCR analysis 
stage using nuc primers. The pleural fluid derived template DNA was from sample 3 (see Table 20 
above). Average Cq values: p(nuc) = 15.35; p(nuc)+PF = 15.78; PF = 30.19; Water = 30.54. Error 
bars show standard error. Raw data can be found in Appendix 9.12.1. 
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The samples not containing the p(nuc) standard (PF and water) showed equivalent average Cq 
values, confirming that the pleural fluid did not contain a background level of S. aureus which 
would interfere with these experiments. For the samples containing the p(nuc), the average Cq 
values were also equivalent regardless of the presence of the extract derived from pleural fluid 
samples. This demonstrated that there were no significant inhibitors present in the pleural fluid 
DNA extract which may affect the results in the S. aureus specific qPCR run with the nuc_qPCR 
primers. It therefore follows that, as all components in the generic 16S rRNA run are identical, the 
only potential factor remaining which could affect the results is the 16S rRNA primers themselves. 
5.4.3. qPCR inhibition test: 16S rRNA primers 
The same procedure was carried out using the 16S rRNA primers to determine whether the 
efficacy of the qPCR analysis stage would be impaired by the pleural fluid when using this primer 
set. It was expected that the pleural fluid would contain a background level of microorganisms 
which would be detected by the 16S rRNA primers. Therefore, it was expected that the two sample 
types not containing the p(16S) standard would not produce equivalent results to each other with 
this primer set as they did with the nuc primers. Two technical replicates for each sample were 






Figure 23 – Results from qPCR test to determine impact of pleural fluid on the qPCR analysis 
stage using 16S rRNA primers. The pleural fluid derived template DNA was from sample 3 (see 
Table 20 above). Average Cq values: p(16S) = 17.92; p(16S) + PF = 18.07; PF = 24.47; Water = 
28.68. Error bars show standard error. Raw data can be found in Appendix 9.12.2. 
This experiment was to determine if the signal produced by p(16S) would be masked by anything 
present in the clinical sample. The sample containing DNA extract derived from pleural fluid but no 
p(16S) standard showed the background level of microorganisms present in the pleural fluid; this 
sample showed a difference to the water sample as expected, but importantly it also showed a 
significant difference to the two samples containing p(16S). As there was a significant difference 
between the PF and the two p(16S) samples, it was not expected that the background level of 
organisms in the pleural fluid would have a significant impact on either of the p(16S) samples due 
to the exponential nature of qPCR. The two p(16S) containing samples showed equivalent average 
Cq values, this suggests that the presence of the pleural fluid had no significant impact on the 
efficacy of the qPCR analysis when using 16S rRNA primers. 
5.4.4. Impact of pleural fluid on BB+P/C DNA extraction efficacy 
Once it had been demonstrated that the pleural fluid did not contain any inhibitors which would 
significantly affect the qPCR analysis stage, all DNA extracts (Table 20, above) were analysed. 
This experiment was to determine whether the use of a complex clinical sample would impair the 
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efficacy of the extraction stage; this was achieved by using qPCR to compare DNA extracts either 
from a clinical sample or from a pure culture of S. aureus. As it had already been established that 
the pleural fluid used had no significant impact on the qPCR analysis stage with each primer set, 
any differences seen must be due to the extraction stage itself. 
First, qPCR analysis using the Staphylococcus aureus specific nuc primers was carried out on all 
DNA extracts from the spiking experiments (Table 20, above). Average Cq values were taken for 
each sample type and plotted as a bar chart (Figure 24, raw data in Appendix 9.13.1). The qPCR 
analysis showed the same pattern for both the PBS and the PF sample types; both the un-spiked 
PBS and un-spiked PF samples showed significantly higher Cq values than the two spiked 
samples (PBS+JE2 and PF+JE2). The un-spiked PBS sample did have a slightly higher average 
Cq value than the un-spiked PF sample, this was to be expected as the clinical sample was far 
more complex than the blank sample of PBS and due to the exponential nature of a PCR reaction, 
slight differences have more of an impact at the higher Cq values. 
Furthermore, the two spiked samples showed comparable Cq values, reflecting the similar quantity 
of S. aureus detected in both sample types; the similarity between the PBS+JE2 and PF+JE2 
samples indicates that there was no significant loss of target material during the DNA extraction 
step despite the complexity of the clinical sample (PF+JE2). Although a difference was detectable 
between the two un-spiked samples, the lack of a significant difference between the two spiked 
samples shows that any impairment the clinical sample may have on the efficacy of the extraction 































































Figure 24 – Results from qPCR test to determine impact of pleural fluid on the BB+P/C DNA 
extraction method when using nuc primers. Both the PBS based samples and the pleural fluid 
based samples showed same pattern, indicating that the presence of pleural fluid does not reduce 
the efficacy of the DNA extraction method or inhibit the qPCR analysis. Average Cq values: PBS = 
25.84; PBS+JE2 = 15.79; PF = 23.92; PF+JE2 = 15.90; p(nuc)2x107 = 12.00; p(nuc)2x106 = 
14.05; p(nuc)2x105 = 16.24; Water = 0.00. Error bars show standard error. Raw data can be found 
in Appendix 9.13.1 
qPCR analysis using the generic 16S rRNA primers was also carried out on these same DNA 
extracts (Table 20, above). Again, average Cq values were taken for each sample type and plotted 
as a bar chart (Figure 25; raw data in Appendix 9.13.2). The PBS samples showed the same 
pattern with the 16S rRNA primers as they did with the nuc primers, this was expected as the vast 
majority of organisms present in these samples should be S. aureus and any cells detected with 
the nuc primer set should also be detected with the 16S rRNA primers. The pleural fluid samples 
also followed the same pattern, however the difference between the two un-spiked samples was 
far greater than in the nuc qPCR analysis. The un-spiked PF sample was expected to show a 
lower Cq value than the un-spiked PBS sample due to a background level of microorganisms in the 
pleural fluid, this likely accounts for the greater difference in these samples when using 16S rRNA 
primers rather than nuc primers. Despite this, the two spiked samples again show very similar Cq 
values, showing that the composition of the clinical sample did not cause any significant loss of 
efficacy in the qPCR analysis stage. Regardless of appearing to be relatively similar to the samples 
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containing the JE2 spike, the un-spiked PF sample is significantly different to the two spiked 
samples due to the logarithmic nature of qPCR, with each 1 Cq difference representing a doubling 





























































Figure 25 – Results from qPCR test to determine impact of pleural fluid on the BB+P/C extraction 
method when using 16S rRNA primers. Both the PBS based samples and the pleural fluid based 
samples showed same pattern, indicating that the presence of pleural fluid does not reduce the 
efficacy of the DNA extraction method or inhibit the qPCR analysis. Average Cq values: PBS = 
33.11; PBS+JE2 = 20.98; PF = 25.25; PF+JE2 = 21.22; p(16S)2x107 = 17.08; p(16S)2x106 = 
20.42; p(16S)2x105 = 23.66; Water = 32.30. Error bars show standard error. Raw data can be 
found in Appendix 9.13.2.  
The spike used in these experiments was a 10µl aliquot of liquid culture of the S. aureus strain 
JE2. The culture contained 1.83x109 CFU/ml, meaning the 10µl spike contained approximately 
1.83x107 CFU of JE2. The samples were eluted in 60µl of low-EDTA TE buffer and 1µl of this DNA 
extract was used for the qPCR analysis, therefore, the Cq values produced by the four test 
samples (PBS, PBS+JE2, PF and PF+JE2) are representative of 1/60th of the initial samples. To 
calculate absolute quantities of S. aureus in each sample, a standard curve was produced from the 
p(nuc) and p(16S) standard samples used at 2x107, 2x106 and 2x105 copies per µl (Figure 26). 
Copy numbers of the nuc gene and 16S rRNA gene were then interpolated from this standard 
curve and used to calculate the number of cells thought to be in the sample (Table 21). As S. 
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aureus has a single copy of nuc, the copy numbers interpolated from the nuc standard curve were 
directly proportionate to the number of cells in each sample. However, S. aureus strain JE2 has 5 
copies of the 16S rRNA gene; it was assumed that the vast majority of microorganisms present 
would be from the JE2 spike, so the copy numbers interpolated from the p(16S) standard curve 
were divided by 5 to calculate the number of cells in each sample. The spike contained ~1.83x107 
cells and the DNA was resuspended in 60µl, meaning that in each 1µl of DNA extract is expected 
to represent ~305,000 cells (1.83x107/60). 


































Figure 26 (A) – Standard curves for each plasmid standard used in qPCR experiments to 
determine impact of pleural fluid on BB+P/C DNA extraction efficacy. A) p(nuc) standard curve; B) 
p(16S) standard curve. Standard curves from plasmids at a known copy number were used to 












































Figure 26 (B) – Standard curves for each plasmid standard used in qPCR experiments to 
determine impact of pleural fluid on BB+P/C DNA extraction efficacy. A) p(nuc) standard curve; B) 
p(16S) standard curve. Standard curves from plasmids at a known copy number were used to 
interpolate the copy number from the samples with unknown copy numbers. 
 
 
nuc_qPCR primers 16S rRNA primers 
Avg. Cq 
value 










PBS 25.84 3.76 4 33.11 312.28 62 
PBS + JE2 15.79 286,996.40 286,996 20.98 1,356,566.34 271,313 
PF 23.92 32.07 32 25.25 71,432.54 14,287 
PF + JE2 15.90 253,112.90 253,113 21.22 1,146,652.84 229,331 
Water (NTC) >40 0 0 32.30 547.92 110 
Table 21 – Absolute number of cells predicted to be in the 1ul of each sample which was analysed 
by qPCR. Copy number determined by interpolation from standard curves (Figure ). *Number of 





The pleural fluid samples were anticipated to contain excessive amounts of human DNA as well as 
DNA from other microorganisms present in the raw clinical sample. It was hypothesised that this 
disproportionate amount of human DNA compared to the DNA from the JE2 spike may prevent 
accurate quantitation of the spike in the clinical samples. However, this experiment has 
demonstrated the capability of the extraction method and the specificity of the qPCR analysis to 
accurately detect S. aureus in clinical samples despite the background level of human DNA. 
Unfortunately, it was not possible to confirm the quantity of human DNA in the pleural fluid samples 
due to ethical constraints regarding the amplification of patient DNA without informed consent. 
These analyses aimed to evaluate the impact that a DNA extract derived from a complex clinical 
sample might have on the BB+P/C DNA extraction method and its associated qPCR analysis with 
both S. aureus specific nuc primers and generic bacterial 16S rRNA primers. It was possible to 
determine the presence and absolute quantity of amplifiable DNA in the spiked and un-spiked 
samples for both the simplistic PBS samples and the complex clinical samples of pleural fluid, with 
the spiked samples showing comparable results for both primer sets. Through this comparison, it 
was possible to determine that there was no significant impact on the acquisition of accurate and 
reliable results when using the BB+P/C DNA extraction method on these complex clinical samples 




6.1. Comparison of methods 
Three DNA extraction methods were compared in this project, a kit-based method and two non-kit-
based methods. Most DNA extractions performed in modern laboratories now utilise one of the 
many commercial DNA extraction kits to simplify and expedite the process of obtaining DNA from a 
bacterial culture. This is suitable for studies in which DNA is extracted from a pure culture, however 
if the composition of the sample is unknown, contamination from the ‘kit-ome’ can significantly 
impact the results of the study [54]. Furthermore, yield can be significantly influenced by the DNA 
extraction protocol used on complex microbial communities [55], this could have a significant 
impact when attempting to extract 100% of the DNA present in a sample. 
Prior to the comparison of methods stage of this project, it was determined through laboratory-
based experimentation that there was no significant difference in yield when using lysostaphin 
compared to Metapolyzyme with the Roche kit. Therefore, it was decided that MetaPolyzyme 
would be used for all further kit-based extractions (Met+Kit). The three methods were then directly 
compared, with the BB+P/C method producing the highest yield, followed by the Met+P/C method; 
both of which utilise phenol/chloroform for DNA purification. The Met+Kit method produced the 
lowest yield and uses a spin-column approach for DNA purification. Effect of sample preparation 
was then investigated by comparing differences in yield from fresh and frozen S. aureus samples. 
For the BB+P/C and Met+Kit methods there was no significant difference between extracting DNA 
from fresh samples compared to frozen samples of S. aureus, however there was a significant 
difference when using the Met+P/C method. Relative sensitivity of each extraction method 
compared to the other two methods was determined by completing DNA extractions on serially 
diluted samples. The BB+P/C method was able to extract a higher yield from more diluted 
samples, followed by the Met+Kit method, with the Met+P/C method having the lowest sensitivity of 
the three. In summary, the BB+P/C method was deemed the most effective for extracting DNA 
from samples with a low bacterial load when compared with the other two methods, without being 
significantly affected if samples were frozen before processing. 
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Throughout, these three DNA extraction methods were compared using a series of T-tests to 
determine the statistical significance of any observed differences. On reflection, it would have been 
more appropriate to use an ANOVA to analyse all three methods simultaneously, followed by a 
post-hoc test (such as the Tukey test) to provide deeper insight into any statistically significant 
differences. Furthermore, a multivariate ANOVA could have been used to determine statistical 
significance between the three methods when compared by qPCR across three different dilutions 
(Figure 13). 
6.2. DNA extraction principles 
DNA extraction can be divided into three key steps: Lysis, Purification and Precipitation [56]. The 
Met+Kit and the Met+P/C method rely upon enzymatic lysis of cells. MetaPolyzyme is an enzyme 
mix containing mutanolysin, achromopeptidase, lyticase, chitinase, lysostaphin and lysozyme; 
these six enzymes are hydrolytic against the cell wall, and in combination are thought to be able to 
lyse all Gram-positive and Gram-negative bacterial cells, as well as all yeast and fungal cells. For 
lysis of staphylococcal species, lysostaphin is included in this MetaPolyzyme mix. Lysostaphin has 
hexosaminidase, amidase and endopeptidase activity, enabling cellular lysis via cleavage of 
polyglycine crosslinks in the cellular wall of staphylococcal species [57, 58]. 
The BB+P/C method relies upon mechanical lysis of cells through physical bead-beating. The 
Lysing Matrix E (LME) tubes used in this method contain a mixture of 1.4mm ceramic spheres, 
0.1mm silica spheres and one 4mm glass bead. The range of bead sizes allows mixed samples to 
be entirely homogenised, providing highly efficient cellular lysis. Cellular lysis in the BB+P/C and 
Met+P/C methods are also facilitated by use of CTAB, a cationic detergent which promotes 
instability of biofilms and cellular lysis [59] whilst maintaining the integrity of DNA [60, 61]. 
For DNA purification, the Met+Kit method uses a spin-column based approach. A binding buffer is 
added to each sample which facilitates binding of nucleic acids to glass fibres manufactured into 
the filter tubes which come with the kit. The sample is then subject to a series of centrifugation-
based wash steps to remove cellular components, resulting in the sample only containing the DNA 
bound to the glass fibres in the filter tube. After purification, the elution buffer releases the DNA is 
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from the fibres and is collected in a microcentrifuge tube in a final centrifugation step; this step 
replaces more traditional DNA precipitation techniques. 
DNA purification in the BB+P/C and Met+P/C methods uses phenol:chloroform:isoamyl alcohol. 
Water is the main solvent for the samples used, so two distinct phases form when phenol is added 
as it is immiscible with water. Mixing the sample thoroughly and then centrifuging allows many 
contaminants in the sample to partition into the phenol-containing phase, while the DNA remains in 
the aqueous/water phase. The DNA is then concentrated and further purified from salts in the 
precipitation step where the precipitated DNA is repeatedly washed with ice-cold 70% ethanol. 
DNA yield is enriched by use of linear polyacrylamide (LPA), which co-precipitates with DNA, 
increasing the amount of DNA recovered from each sample by increasing the amount of DNA 
which precipitates and reducing the amount of DNA lost during the ethanol wash. LPA is inert, so 
has no downstream effects during PCR or qPCR steps. LPA is very sensitive and is able to 
precipitate picogram amounts of DNA fragments larger than 20 base pairs from a sample [62], 
making it ideal for use with low-yield samples such as pulmonary clinical samples. Furthermore, 
LPA does not interfere with A260/280 readings, so does not affect DNA quantification [63]. 
6.3. BB+P/C DNA extraction method 
The protocol for the BB+P/C DNA extraction method was originally produced by Dr Michael Cox 
(University of Birmingham) and Dr Leah Cuthbertson (Imperial College London) under the 
supervision of Professor Cookson and Professor Moffatt at Imperial College London, as MG-SOP-
0082 (Molecular Genetics and Genomics Standard Operating Procedure). It was provided for use 
in this project by Dr Michael Cox. 
The original protocol included preparation steps for a wide range of sample types. For this study, 
the most relevant were the preparation steps required for processing bacterial isolates, or 
pulmonary samples of bronchoalveolar lavage and pleural fluid. The preparation steps for both 
sample types included the addition of Hexadecyltrimethylammonium bromide (CTAB) for cellular 
lysis, CTAB is a cationic detergent with a structure containing quaternary ammonium compounds 
(QACs). The mode of action of QAC containing detergents is through electrostatic stresses 
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between the positive charge of the QACs and negatively charged sites on the microbial cell wall, 
resulting in lysis of the cell [59]. 
The next step in the extraction protocol is the addition of aluminium ammonium sulphate (AAS) to 
the sample, AAS is a flocculating agent which coagulates any dissolved organic matter which may 
be present in the sample [64]. As some types of organic matter may co-precipitate with DNA, the 
addition of AAS helps to improve the purity of the DNA after extraction. Following the addition of 
AAS, the sample is transferred to an Lysing-matrix E (LME) tube which contains 1.4mm ceramic 
spheres, 0.1mm silica spheres and one 4mm glass bead [65]. These tubes are used for the 
physical bead-beating of complex samples, such as tissues, and contain a range of bead sizes to 
maximise the amount of physical disruption. 
Phenol:chloroform:isoamyl alcohol (PCI) is then added to each sample and the sample is 
subjected to physical bead-beating before being centrifuged. Phenol and water are immiscible, so 
upon addition to the sample, two phases are formed: a water-based (aqueous) phase on top of a 
more dense phenol-based (organic) phase. The bead-beating stage has two functions: firstly, it 
causes physical degradation of the cells in the sample, allowing the release of nucleic acids; and 
secondly, it thoroughly mixes the sample. Samples are then centrifuged, facilitating the reformation 
of the two phases. Mixing the sample well allows all sample components to come into contact with 
both of the available solvents: water and phenol. Water is a more polar solvent than phenol, and as 
polar compounds are generally more soluble in more polar solvents, the polar nucleic acids will 
remain in the aqueous phase. However, when proteins are exposed to a less polar solvent, such 
as phenol, their tertiary conformation changes due to the less-polar amino acids moving to the 
exterior of the protein, effectively denaturing it [66]. This less tightly folded state is more chemically 
stable for the protein but is prevented from forming in more-polar solvents, such as water. 
Therefore, when proteins are in a sample containing both phenol and water, they will remain in the 
phenol-based organic phase. When the sample is centrifuged, the phases separate into their 
distinct sections, also separating the proteinaceous material from the nucleic acids. Chloroform has 
a much higher density than water, so using a phenol:chloroform mix rather than just phenol 
prevents inversion of the phases [67]. This is especially useful when the exact sample composition 
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is unknown, such as when using clinical samples. The increased density also reduces the size of 
the interphase layer, reducing the opportunity to contaminate the aqueous phase when separating 
it from the organic phase. Isoamyl alcohol is also added as it is an anti-foaming agent [67], 
preventing foaming during the bead-beating process. 
After the proteins have been separated from the nucleic acids in the sample, chloroform:isoamyl 
alcohol (CI) is added and the sample is centrifuged again. The additional chloroform added 
removes any remaining phenol from the aqueous layer, further purifying the sample by preventing 
any residual phenol from having any downstream effects on the sample. Again, isoamyl is included 
as an anti-foaming agent. The aqueous phase is then transferred to a new microcentrifuge tube 
containing a very small amount of linear polyacrylamide (LPA). At this point, the protocol provides 
the option to perform a double extraction. This takes the remaining sample in the LME tube and 
exposes it again to all previous steps of the protocol from the addition of the CTAB buffer to the 
removal of the aqueous phase. This can increase the yield obtained from the sample and is useful 
when attempting to extract as close to 100% of the DNA in the sample as possible. 
The microcentrifuge tube which the aqueous phase is transferred to contains LPA, which is a co-
precipitant of DNA and enables the precipitation of picogram amounts of nucleic acids in a sample 
[62, 68]. Being able to recover such small quantities of DNA is incredibly useful both when 
attempting to extract DNA from low-yield samples, and when attempting to extract 100% of the 
DNA present in a sample. LPA is synthetically produced which reduces the likelihood of it 
containing any contaminating nucleic acids compared to chemicals derived from a biological 
source [69]. It is also a chemically inert substance [70], so will not have an influence on any 
downstream applications, such as qPCR analysis of DNA extracts. 
Polyethylene glycol in a salt solution (PEG/NaCl) is added to the aqueous phase of the sample. 
PEG is a neutral polymer which is commonly used for the precipitation of nucleic acids through 
salt-induced DNA condensation. The high concentration of salt present in the PEG/NaCl solution 
neutralises the negative charge of the phosphate backbone [71] and the PEG readily binds to 
substantial amounts of water, allowing the neutralised DNA molecules to aggregate [72]. 
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After 18 hours, the sample is centrifuged and the PEG/NaCl solution removed. Following this, the 
pellet is washed several times with ice-cold ethanol to remove any precipitated salts remaining 
from the PEG/NaCl solution. After washing, the sample is left to air dry, allowing any residual 
ethanol to evaporate, and the pellet is resuspended in a low-EDTA TE buffer. TE buffer contains 
tris(hydroxymethyl)aminomethane (Tris) and ethylenediaminetetraacetic acid (EDTA); tris is a 
commonly used pH buffer, and EDTA chelates cations to protect the DNA sample from 
degradation. A low-EDTA TE buffer is used as, at high concentrations, EDTA may have an 
inhibitory effect on PCR by chelating the Mg2+ cations required for an effective PCR reaction. 
However, at low concentrations, EDTA can improve the efficiency of PCR by chelating any 
contaminating ions present as it has a relatively low affinity for magnesium compared to other 
metal ions which may inhibit PCR, such as Ca2+, Pb2+, Cd2+ and Hg2+ [73]. If present, these ions 
with a higher affinity to EDTA will displace the magnesium and bind to EDTA, preventing them from 
binding to the DNA polymerase enzyme and potentially inactivating it, reducing PCR efficiency. 
This DNA extraction protocol should be carried out on ice as much as possible, and centrifugation 
steps should be performed in a temperature controlled centrifuge at 4°C. Keeping the sample cold 
throughout the purification stage of the extraction protocol reduces the activity of any DNases 
which may be present in the original sample, increasing the final yield of DNA. Keeping the sample 
cold during the precipitation stage reduces the solubility of the aggregated DNA, facilitating nucleic 
acid precipitation. The resuspended DNA extract is stable to be stored at -20°C or -80°C until 
required, however repetitive freezing and thawing is not recommended as it may damage the DNA 
in the sample. 
6.4. Phase lock gel 
After performing the BB+P/C DNA extraction method repetitively on similar types of samples, it 
became clear that there was some variability between technical and biological repeats of the same 
sample. One potential technique to reduce this variation is to use phase lock gel [47] when 
decanting the DNA-containing aqueous phase into a fresh tube during the extraction. After adding 
phenol:chloroform:isoamyl alcohol (PCI) and centrifuging the sample, it settles into two distinct 
phases: an aqueous phase above an organic phenol-containing phase; this occurs as phenol is 
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denser than water. The proteinaceous material from the cells settles in the organic phase, with 
some cellular debris also settling between the phases as an interphase layer. The aqueous phase 
contains the DNA and must be removed without disrupting the interphase as if this layer is 
disrupted it will contaminate the sample. This step introduces sample variation due to human error 
as the removal of the entire aqueous phase is confirmed by eye and is reliant on the individual’s 
abilities with a pipette. 
Phase lock gel is a viscous liquid which settles between the organic and aqueous phases after 
centrifugation of the sample, forming a barrier and preventing the opportunity to interrupt the 
interphase (Figure 27). This makes it significantly easier to decant the aqueous phase without 
contaminating the sample, as well as reducing the amount of DNA discarded due to human error. 
Furthermore, the use of phase lock gel provides increased protection from the phenol contained in 
the organic phase, making the procedure less hazardous to the health of the individual performing 
the extraction. 
 
Figure 27 – Diagram showing how addition of phase lock gel (PLG) forms a barrier between the 
aqueous and organic phases, allowing removal of the DNA-containing aqueous phase without 
interrupting the interphase layer of protein and cell debris. 
The experiments which were performed to assess the impact of phase lock gel on the BB+P/C 
method demonstrated that it is an effective method to reduce the variation in yield between 
samples, and also had the further benefit of reducing the loss of sample material during the DNA 
extraction process. One caveat with the experimentation performed to assess the impact of phase 
lock gel is the use of the NanoDrop spectrophotometer as the sole method of DNA yield 
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quantification as there was no way of identifying any factors within the samples which may cause 
interference with the A260/280 reading. Confidence in the reading obtained was increased by 
taking three independent readings per sample, however if the whole sample was contaminated this 
provided no explanation as to why yield may have been affected. Interestingly, the results showed 
unequal variance for the samples with PLG compared to the samples without PLG; therefore for 
these samples the parameters of the t-test carried out were set to assume unequal variance. 
Following these experiments, phase lock gel was implemented in all BB+P/C DNA extractions 
performed in order to reduce artificial sample variability.  
The phase lock gel used in these experiments was produced in-house due to the high cost of 
buying it commercially. The phase lock gel produced was suitable for the requirements of this 
project, however after a period of 6 months, the gel would begin to separate back into its 
constituent components. Therefore, for a longitudinal study the recommendation from this project 
would be to purchase the more costly, but quality controlled and more stable, commercial phase 
lock gel.  
6.5. Limit of detection (LoD): Extended serial dilution experiments 
To find the limit of detection (LoD) of the BB+P/C DNA extraction method and the associated 
qPCR analysis, DNA was extracted from a serial dilution series of S. aureus strain JE2. Two 
different primer sets (nuc_qPCR and 16S rRNA) were used, with an independent LoD determined 
for each set.  
The qPCR analysis performed on the DNA extracts using the nuc_qPCR primers showed that this 
method is able to extract and detect S. aureus cells in a 1ml sample down to a level of 1,000 cells. 
This is almost the lowest dilution that would be possible to detect under the conditions used; this is 
because each 1ml sample produced a DNA extract of 60µl, and only 2µl of the total 60µl DNA 
extract was used in the qPCR analysis stage. This 2µl represents only 1/30th of the original sample; 
the theoretical number of cells represented in qPCR analysis for each dilution sample used in 
these experiments is shown in Table 22. 
To demonstrate the issue, imagine a hypothetical 1ml sample containing 100 copies of a gene; 
assuming perfect extraction efficiency, the 60µl DNA extract produced would contain all 100 copies 
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of the gene. The 2µl which is then taken for qPCR analysis would theoretically only contain 3 
copies of the gene. Another hypothetical sample containing only 10 copies of a gene, treated in the 
same way, would theoretically have 0.3 copies in the 2µl used for qPCR analysis; probability 
dictates that this sample would usually not produce a result despite the DNA extract containing 10 
copies of the gene. Therefore, even if the extraction efficiency is 100%, not all organisms in the 
sample will be detected in qPCR when processed under these conditions as the whole DNA 
extract is not analysed. This must be considered if attempting to calculate absolute values from the 
Cq values produced and it may be preferable in future studies to resuspend the DNA in a lower 
volume and analyse the entire DNA extract in the qPCR run. This has the caveat of not permitting 
technical repeats of a sample at any stage, however biological repeats are possible to maintain the 
scientific integrity of a study. Samples were not processed in this way for this project as technical 
repeats from the same sample were essential for investigating the fundamental abilities of this 
DNA extraction method and qPCR analysis. 
The qPCR analysis performed found the LoD cut-off for a 1ml sample to be 1,000 cells when using 
the nuc primers. Following the extraction and resuspension in 60µl, the 2µl of this sample that was 
used for qPCR theoretically contained ~33 copies of the nuc gene (Table 22). This accounts for the 
difference in LoD seen between these JE2 samples (nuc LoD = 1x103 cells) and the p(nuc) 
samples which were found to have an LoD of 20 copies. As expected, the 16S rRNA primers could 
not reliably detect the S. aureus cells to the same extent as the nuc primers, likely due to being 
less specific to their target. 16S rRNA analysis was able to reliably detect down to a dilution of 
10,000 cells in 1ml; the 2µl from this sample used for qPCR analysis theoretically represented 
~333 cells (Table 22). Again, by accounting for the actual number of cells represented in the qPCR 
analysis stage, the LoD for the extracted samples (16S LoD = 1x104) is comparable with the LoD 







Theoretical CFU of S. aureus 
JE2 in 60µl DNA extract 
Relative number of cells 
represented in 2µl used for 
qPCR analysis (CFU/30) 
1 1 x 109 *Not used for qPCR 
2 1 x 108 3,333,333 
3 1 x 107 333,333 
4 1 x 106 33,333 
5 1 x 105 3,333 
6 1 x 104 333 
7 1 x 103 33 
8 100 3 
9 10 0 
10 1 0 
Blank 0 0 
Table 22 – Number of cells represented in qPCR for each dilution used in LoD experiments. Total 
DNA was resuspended in 60µl and only 2µl of this was used for qPCR. *sample not used for qPCR 
due to excessive amount of DNA which would affect acquisition of data for all samples. 
This difference between the number of copies present in the total 60µl DNA extract compared to 
the number of copies in the 2µl analysed by qPCR is the main factor accountable for the difference 
in LoD between the plasmid standards (p(nuc) = 20 copies, p(16S) = 200 copies) and extracted 
samples of JE2 (nuc = 1x103 cells, 16S = 1x104 cells). Following the BB+P/C extraction, the DNA 
is resuspended in 60µl in order to produce enough DNA to perform any experiments with multiple 
repeats if necessary, however this volume could theoretically be reduced in future studies and LoD 
scores recalculated if the scores determined by this project are not sensitive enough for the 
intended use. The LoD of the BB+P/C method will be dependent on the exact conditions used, but 
has been demonstrated in this project to be at least sensitive enough to detect 1x103 cells in 1ml of 
sample using the nuc primers and 1x104 cells when using the 16S rRNA primers. 
The method developed in this project is intended for use on clinical pulmonary samples which are 
expected to contain far higher quantities of microorganisms than 1,000 cells per ml; the clinical 
threshold for a positive BAL sample is currently 1x104 CFU/ml [17], which is ten-fold higher than 
the LoD of this method when using nuc primers for qPCR analysis and equal to the LoD when 
using 16S rRNA primers. Furthermore, the starting volume of clinical samples used will not be 
limited to a maximum of 1ml, meaning that it may be possible to detect far lower quantities of 
microorganisms per ml by increasing the initial volume of sample used. For future work using this 
method, it will be crucial to record the starting volume of each sample used, the volume of buffer 
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used for resuspension of DNA, and the volume of DNA extract used for qPCR analysis. All three of 
these variable factors will impact the LoD of the method and are also vital to consider when 
calculating absolute quantities of organisms in a sample against a standard curve.  
6.6. Clinical samples and pleural fluid spike experiments 
The purpose of the experiments using pleural fluid was to determine whether the use of complex 
clinical samples would have an impact on the results acquired through the BB+P/C DNA extraction 
method. This was important to do as the extraction method being developed in this project is 
ultimately intended for use on clinical samples. The first set of experiments using pleural fluid 
determined that the qPCR analysis stage was not significantly impaired through use of a DNA 
template derived from clinical pleural fluid samples. The second set of experiments was an 
extension of this to determine the effects of pleural fluid on the entire BB+P/C DNA extraction and 
qPCR analysis process combined. These experiments found that the results were not significantly 
different between the simplistic samples and the clinical samples containing DNA derived from 
pleural fluid; therefore, it was concluded that the efficacy of the process was not significantly 
impaired when processing the clinical samples. 
Pleural fluid was used for these experiments as it was not possible to obtain any bronchoalveolar 
lavage (BAL) samples. The samples were required for use during the summer months and, as the 
incidence rate of pneumonia is higher during the winter [1], there were very few patients who 
required a bronchoalveolar lavage. Furthermore, the patients with chronic disease who require a 
bronchoalveolar lavage more regularly are often unconscious and therefore are unable to provide 
consent for the use of their lavage fluid in research. Therefore, it was far easier to obtain ethically 
approved samples of pleural fluid compared to bronchoalveolar lavage. The patient who provided 
the pleural fluid used in this study required pleurocentesis due to lymphoma. 
The pleural fluid used was a suitable replacement for BAL as it was an exudate which had 
originated within the lungs and entered the pleural cavity due to the inflammation caused by the 
lymphoma. As the pleural effusion was due to lymphoma, rather than due to an active lung 
infection, the samples were far more valuable for assessing the efficacy of this DNA extraction 
method. This is because the microbial load of this pleural fluid would be far lower than if the 
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sample was obtained from a patient with an active infection. However, it is important to note that 
the exact composition of a clinical sample may differ significantly between patients, and this 
specific pleural fluid sample which was used may not be representative of all pleural fluid samples. 
Therefore, any future work using this DNA extraction method on clinical samples should consider 
this and it is recommended that they independently verify the efficacy of the process with their 
specific samples if possible. 
The use of a more complex sample type, such as pleural fluid, had potential to impair the DNA 
extraction process at either of the two key stages: the DNA extraction itself, or the qPCR analysis 
of the DNA extracts. Any loss of efficacy in the clinical samples compared to the PBS samples at 
the extraction stage was likely to be due to components in the sample which could disrupt the 
individual steps of the DNA extraction protocol by altering characteristics such as pH or density. 
Density is important as a change could result in inversion of the sample with the aqueous phase 
locating below the organic phase, making it difficult to recover the DNA without contaminating the 
sample. Furthermore, the sample must remain between pH 7 and pH 8 in order for phenol-
chloroform based extractions to work; if pH decreases, the negative charges of the DNA phosphate 
backbone would be neutralised by the increased concentration of H+ ions, allowing the DNA to 
dissolve into the organic phase rather than the aqueous phase. This would prevent the isolation of 
DNA from the proteinaceous material present in the sample. Fortunately, the pH of pleural fluid is 
typically between pH 7.60 and pH 7.66 [74], so should not impact the DNA extraction in most 
cases. Loss of quality at the qPCR analysis stage would likely be due to either the presence of 
PCR inhibitors, or the substantial amount of human DNA present in clinical samples. 
The first set of experiments examined the impact of pleural fluid on the qPCR analysis stage. 
These experiments consisted of comparisons between two sets of samples, one of which was 
spiked with a DNA extract derived from a clinical sample of pleural fluid. By comparing the Cq 
results produced from qPCR on these samples against samples not containing the pleural fluid 
derived DNA spike, it was possible to confirm that the pleural fluid used in this experiment did not 
impair the qPCR analysis stage. This was the case for both the S. aureus specific nuc primers and 
for the generic 16S rRNA primers. Furthermore, the first qPCR experiment using nuc primers 
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confirmed that the pleural fluid used did not contain a background level of S. aureus which would 
interfere with the results from these analyses. Pipetting error was identified as a potential source of 
inaccuracy in this qPCR stage as only 1µl of DNA extract was added to the qPCR reaction; 
variation due to pipetting error could be diminished by using a minimum of 2µl of DNA template in 
qPCR analysis for any future studies. 
The second set of experiments examined the impact of pleural fluid on the BB+P/C DNA extraction 
stage by comparing DNA extracts from two samples of pleural fluid against two samples of PBS; 
for each sample type, one was spiked with S. aureus strain JE2. The similarity in Cq values for the 
spiked samples in both sample types demonstrated that the detection of S. aureus was not 
significantly impaired in the pleural fluid derived samples compared to the PBS samples. The 
similarity in Cq values using nuc primers for the un-spiked samples showed that there was no 
significant background level of S. aureus in the pleural fluid; however the difference in Cq values 
when using the 16S rRNA primers suggested that there was a background level of other 
microorganisms in the pleural fluid. This was expected as the pleural fluid was likely to contain a 
low level of organisms from the patient’s natural pulmonary microbiome. 
A major concern prior to this experiment was that the number of human cells present in the sample 
would provide an overwhelming amount of human DNA, significantly inhibiting the detection of 
bacterial DNA in the sample. As the pleural fluid was obtained from a patient with lymphoma it was 
likely to have a higher proportion of human cells (compared to bacterial cells) than if it was from a 
pneumonia patient with an active microbial infection. Therefore, the pleural fluid used represents a 
scenario with a higher than usual number of human cells present in the sample; despite this, the 
efficacy of the BB+P/C DNA extraction and qPCR analysis process was not significantly inhibited 
and it can be understood that efficacy would also not be impacted in a sample of pleural fluid from 
a patient with an active infection. 
A serial dilution of the p(nuc) and p(16S) plasmid standards were also run alongside the samples 
in these experiments, allowing the production of a standard curve with known copy numbers for 
each gene. This allowed absolute quantification of the number of cells in each sample through 
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interpolation of copy number from the average Cq value for each sample. Unfortunately, there 
were several caveats associated with the absolute quantification performed in these experiments. 
The first is that it was not possible to definitively establish the accuracy of the absolute 
quantification performed. The JE2 liquid culture used was at an estimated 1.83x109 CFU/ml, 
however this was calculated through performing a serial dilution and plating out each dilution, and 
then counting the colonies on the 1x10-6 to 1x10-9 plates and extrapolating up to give the 
approximate CFU/ml of the neat culture. This provided an opportunity for any error due to pipetting 
to be magnified when scaled up from the lower dilutions to the neat culture. 
Furthermore, only 10µl of the neat culture was added to each sample as a 1.83x107 spike, again, 
pipetting error could add significant variability to the number of cells added to each sample. 
Combined, this reduced the confidence in the value designating the expected number of cells in 
each sample (~305,000 cells). The accuracy of the absolute number of cells determined to be in 
each sample may also be impaired by pipetting errors as of the total 60µl DNA extract, only 1µl 
was analysed by qPCR; this error could be reduced in future studies by analysing more than 1µl in 
the qPCR stage. The number of cells detected in each sample showed that the method was unable 
to extract and detect 100% of the cells expected to be in the sample, however it was impossible to 
know the exact number of cells actually present in the sample, and therefore the absolute 
quantification for each sample can only be used as a rough estimate when compared to the 
expected number of cells in the samples. It is useful, however, for comparisons between different 
samples of the same type, such as the spiked vs. un-spiked samples analysed with each primer 
set. 
In addition to this, the absolute quantification of the samples analysed with 16S rRNA primers is 
impacted by the variation in 16S copy number between species. Correcting for 16S rRNA gene 
copy number in microbiome studies remains an unsolved problem [75]; S. aureus strain JE2 has 5 
copies of the 16S rRNA gene in its genome [76], however this number can vary greatly between 
different microorganisms with some having just one copy, and others having as many as 21 copies 
(e.g. Photobacterium damselae [77]). 
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To quantify the number of JE2 cells in the sample in absolute terms, it was assumed that all cells 
present in the sample were S. aureus JE2, however this is highly unlikely to be the case for the 
pleural fluid derived samples. The absolute copy number detected through qPCR was divided by 5 
to determine the number of JE2 cells present in the sample, however if there were organisms with 
different 16S rRNA copy numbers, these would be either over- or under-represented in the 
absolute number of cells quantified in these samples. 
It was calculated that the un-spiked sample of pleural fluid contained approximately 1.4x104 cells. 
Each pleural fluid sample was 5ml, meaning the pleural fluid contained an estimated 2.8x103 cells 
per ml. There is a possibility that the  quantity of cells in the un-spiked pleural fluid increased due 
to cellular growth when transporting the pleural fluid to the University of Bristol or when defrosting it 
at room temperature as human pleural fluid has been shown to be a potent growth media for some 
bacteria [78].   
It is also important to note that these experiments did not prove the absence of inhibitors in the 
pleural fluid sample, only that anything present in these clinical samples had no significant 
impairment on the BB+P/C DNA extraction method and the associated qPCR analyses. It is still 
possible that the DNA extract produced contains various inhibitory components which may impact 
downstream applications, such as if the DNA extract is used for sequencing. Furthermore, every 
clinical sample is unique to each individual patient and therefore may show inherent differences in 
its composition. Therefore, the clinical samples used in future studies may contain inhibiting 
components which were not present in this study, however, despite any differences between 
clinical samples, they will also have many similarities. This study demonstrates that the DNA 
extraction and qPCR analysis was not significantly impaired by using this pleural fluid, and 
therefore it can be concluded that any components common to all pleural fluid samples (and were 
therefore present in the sample used) do not impact the results acquired through the BB+P/C DNA 
extraction method. 
Another factor to consider in future projects concerns the viability of the organisms. This method 
did not include any steps to remove any extracellular DNA present in the sample prior to the DNA 
extraction. Therefore, the method is unable to distinguish whether the organisms present in the 
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pleural fluid were viable at the start of the BB+P/C DNA extraction procedure. Any future work 
must consider their objectives with regard to the viability of organisms within the sample and carry 
out appropriate steps to remove any extracellular DNA prior to starting the BB+P/C DNA extraction 
if only viable organisms are desired. 
6.7. PCR Primers 
6.7.1. nuc primers 
The nuc gene encodes a Staphylococcus aureus specific thermonuclease [79]. Primers for this 
gene were chosen as it is well established as a PCR target for the specific identification of S. 
aureus [80-82], allowing S. aureus presence or absence in a sample to be determined without the 
need to sequence the extracted DNA. The initial nuc primer set used in this project was the 
nuc_Hoegh set. The sequence for these primers was taken from literature and were originally 
designed by a group at the Department of Clinical Microbiology in Odense University Hospital, 
Denmark [40]. They were produced for a project interested in reliable identification of S. aureus in 
clinical microbiological diagnostics, so appeared to be a good primer set to use for this project. 
Unfortunately, it was later discovered that this primer set produced a product with Streptococcus 
pneumoniae strain d39. This was not a concern for the study carried out by Hoegh et al. as the 
samples used in their study were clinical isolates which had been phenotypically identified as S. 
aureus, and therefore there was no possibility of another organism being detected by their nuc 
specific primer set in their experiments. It was also not a concern for the first stage of this project in 
which an extraction method was selected based on DNA extractions from pure cultures of S. 
aureus; however it was evident that this primer set would not be appropriate for the microbiome-
based studies that the extraction method developed in this project is intended for. 
To overcome this obstacle, a new primer set was designed for the S. aureus nuc gene. To produce 
a primer set that would be suitable for all S. aureus strains, multiple sequence alignment was 
performed using sequences for the nuc gene from 31 representative strains of S. aureus. These 
strains were selected from a list of strains used by AureoWiki to compile a pangenome for S. 
aureus [52]. From the multiple sequence alignment it was possible to determine the most 
homologous region of the nuc gene; this conserved region was selected as a target for the primers 
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in order to increase the likelihood of the primer set being suitable for all S. aureus strains. The 
primers designed for this region were nuc_qPCR_F and nuc_qPCR_R and produce a 180bp 
amplicon. 
To assess the S. aureus specificity of these primers, the sequences were entered into the NCBI 
Primer BLAST tool [53]. In order to get the broadest coverage, the ‘nr database’ was selected and 
no organism was specified in the primer pair specificity checking parameters section. Of the 688 
results generated, 682 were S. aureus strains; the only results to not match an S. aureus strain 
were 2 cloning vectors (pSEC-Nuc-OmpH and pFUN), a synthetic construct (pS120+), and 3 
sequences from the very closely related Staphylococcus schweitzeri which is a non-human 
primate-associated organism. S. schweitzeri is phenotypically very similar to S. aureus and has a 
near identical 16S rRNA gene sequence [83] so may not distinguished from S .aureus in most 
microbiome based studies. All products produced in silico were 180bp in length, matching the 
expected amplicon size; this includes the 6 results which did not match an S. aureus strain, 
suggesting that the vectors and synthetic construct identified are likely to contain a copy of the S. 
aureus nuc gene. 
After showing that the primers were, in theory, specific only to the S. aureus nuc gene, it was 
important to ensure the primer set would work in vitro. To do this, a qPCR experiment was 
performed using the nuc_qPCR primers on genomic DNA (gDNA) extracts from the S. aureus 
strain JE2 and the Streptococcus pneumoniae d39 strain which had produced a product with the 
nuc_Hoegh primer set. This experiment clearly demonstrated that a product was produced with the 
S. aureus JE2 template, but not with the S. pneumoniae d39 template. Together with the in-silico 
Primer BLAST test, these results show that these nuc_qPCR primers are suitable for specifically 
detecting S. aureus in a sample. It must be noted that although the primers have been shown to 
only produce a product with S. aureus, clinical samples may contain organisms not included in the 
NCBI database which could produce a product with these primers. Although this is unlikely, it 
means that there cannot be 100% certainty that the product is from S. aureus. To make the primer 
set even more specific to the S. aureus nuc gene, a TaqMan probe could be produced for use in 
80 
 
future experiments, alternatively qPCR products could be sequenced to ensure a direct match with 
the S. aureus nuc gene. 
6.7.2. 16S rRNA primers 
Utilisation of the 16S rRNA gene is the most common genetic-based method for generic bacterial 
identification. This gene is universal to all bacteria as it encodes an essential ribosomal subunit. 
The majority of the 16S rRNA gene is highly conserved, however it contains nine hypervariable 
regions which can be used to identify bacteria based on species-specific sequences. A major 
benefit of using the 16S rRNA gene for bacterial identification is that it bypasses the need to 
culture the organism in vitro for phenotypic identification; this saves a significant amount of time 
and resources for microbiome studies, it is also more accurate than culture based methods as it is 
able to identify organisms which have never been successfully cultured in vitro [84]. Whole 16S 
rRNA gene sequencing can be prohibitively expensive, so to reduce cost, only the fourth variable 
region (V4) was chosen for this study which is 254 base pairs in length in most bacteria, only 
deviating by a few base pairs between organisms [85]. 
V4 is a semi-conserved hypervariable region which can provide phylum level resolution as 
accurately as the full 16S rRNA gene [86], however primer design can introduce biases by 
selecting for or against certain organisms [87]. Mitigating these potential biases requires a primer 
set which incorporates degenerate bases in the sequences of each primer to compensate for the 
target DNA not being fully conserved between organisms. The degenerate primers ensure that 
almost all bacterial species will be captured, however the presence of degenerate bases 
significantly reduce the melting temperature (Tm), and therefore the annealing temperature (Ta), of 
the primer pair as it is determined by the lowest possible combination found in the degenerate 
primer set. 
6.8. PCR 
The degenerate nature of the 16S rRNA primers led to this primer pair having a very low annealing 
temperature which can have an effect on the efficiency of the PCR reaction This may explain why 
after agarose gel electrophoresis of PCR products, the bands were brighter for samples amplified 
using nuc primers than for samples amplified using 16S rRNA primers. Traditional PCR was able 
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to determine presence or absence of DNA from a sample; however, it did not offer the specificity 
required to determine the quantity of a gene in the sample. 
The use of qPCR in this project enabled the quantification of gene products, this works through the 
incorporation and subsequent detection of fluorescent markers attached to the dNTP’s in the 
reaction mix. In order to determine an absolute quantity of DNA in a sample, a standard is needed 
of a known amount of the gene target for each primer set. In this project, a plasmid containing the 
nuc gene from S. aureus strain JE2 (p(nuc)) was produced to be used with the nuc primer set, and 
a plasmid containing the full 16S rRNA gene from Vibrio natriegens (p(16S)) was used for the 16S 
rRNA primer set. Both plasmid standards were used at a quantity of 2x107 copies per µl. 
The 16S rRNA gene from Vibrio natriegens was selected as this species is not found in the human 
lung; it was necessary to choose a standard from an organism which is not typically found in the 
lung microbiome to remove the possibility of false positives due to cross-contamination from the 
standard. The use of plasmid standards at known copy numbers also provided the opportunity for 
absolute quantification of the number of copies of a gene present in a sample; this required a serial 
dilution series of the plasmid standard to be run alongside the samples in the qPCR run, 
production of a standard curve from the Cq results and interpolation of copy number from the Cq 
values of the unknown samples. 
One potential improvement would be the use of digital PCR (dPCR) instead of qPCR. dPCR is 
another quantitative PCR method which has significantly increased sensitivity due to the method 
by which the sample target is measured. dPCR works by partitioning a sample into a vast number 
of individual picolitre sized droplets with either zero or one target molecules contained within each 
before running the thermal cycles. This results in each droplet carrying out a separate reaction. 
After the reaction has taken place, the droplets are analysed and counted as either positive or 
negative, depending on the presence or absence of amplified product in the droplet. 
The contents of the sample can then be quantified based on the proportion of positive to negative 
droplets measured. One of the most recent advancements in dPCR technology is the ThunderBolts 
dPCR system by RainDance technologies which is capable of sequencing the PCR product directly 
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after amplification [88]. This provides the opportunity to determine the precise composition of a 




During this project, three DNA extraction methods were directly compared to determine their ability 
to obtain DNA from low yield samples. The three methods were: 
1. Met+Kit: uses MetaPolyzyme for cellular lysis and the Roche High Pure PCR Template 
Preparation Kit for DNA isolation and purification. 
2. BB+P/C: uses physical bead-beating and CTAB detergent for cellular lysis, and traditional 
phenol/chloroform treatment for DNA isolation and purification 
3. Met+P/C: a combination of the two above methods, using MetaPolyzyme for cellular lysis 
and traditional phenol/chloroform treatment for DNA isolation and purification 
The first experiments performed determined the ability of the Roche kit to use MetaPolyzyme for 
cellular lysis with the same efficiency as Lysostaphin; these experiments showed no significant 
difference in yield between the two enzymatic treatments. Therefore, MetaPolyzyme was 
substituted for Lysostaphin for all other experiments using the Roche kit. 
The three methods were then directly compared for their ability to extract DNA from samples of S. 
aureus JE2 liquid culture. The BB+P/C method produced the greatest yield, followed by the 
Met+P/C method, with the Met+Kit method producing the lowest yield. 
As clinical samples are often frozen before treatment, each of the methods was assessed for their 
ability to extract DNA from fresh and frozen samples of S. aureus JE2 liquid culture. The BB+P/C 
method showed the least variation in yield between fresh and frozen samples, followed by the 
Met+Kit method, with the Met+P/C method showing the greatest difference between fresh and 
frozen samples. Therefore, the BB+P/C method was determined to be the most reliable if the state 
of the samples cannot be controlled. 
The methods were then compared for their ability to extract DNA from low yield samples, this was 
investigated through extracting from a serial dilution of S. aureus JE2 liquid culture from neat to 
1x10-2. Initial comparison through PCR was impaired by the sensitivity of the NanoDrop 
spectrophotometer to provide reliable quantification of the DNA yields at the lowest dilutions. 
Therefore, DNA extracts were compared by qPCR. This found the the BB+P/C method produced 
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the highest yield at all dilutions, most importantly showing a significantly higher yield than the other 
two methods at the 1x10-2 dilution. At this dilution, the Met+Kit produced the next highest yield, 
followed by the Met+P/C method. 
Through these comparisons, the BB+P/C technique was shown to be the most reliable and 
effective of the three methods for extracting DNA from low yield samples and was selected to be 
more rigorously investigated and developed for use on clinical samples of bronchoalveolar lavage 
and pleural fluid. 
To determine the limit of detection (LoD) for the BB+P/C DNA extraction method and the qPCR 
analysis which would be used to obtain results, the qPCR analysis stage was first investigated in 
isolation using the plasmid standards, p(nuc) and p(16S). This showed the qPCR stage to have an 
LoD of 20 copies with the nuc primers and 200 copies with the 16S rRNA primers. 
To determine the LoD of the BB+P/C method and qPCR analysis combined, an extended serial 
dilution was performed on a liquid culture of S. aureus JE2. DNA was extracted from 1ml samples 
containing a range of S aureus JE2 from 1x108 CFU/ml to 1CFU/ml and analysed by qPCR. This 
found the LoD to be 1x103 CFU in 1ml with the nuc primers and 1x104 CFU in 1ml with the 16S 
rRNA primers. The LoD was likely lower for the two stages combined than it was for the qPCR 
stage in isolation due to only using a fraction of the total DNA extract produced for each sample in 
the qPCR analysis performed. 
Once the LoD of the BB+P/C method had been determined, experiments were performed to 
assess the impact, if any, that complex clinical samples could have on the efficacy and accuracy of 
the method. Again, the qPCR stage was assessed in isolation prior to investigating the complete 
method. For these experiments, a sample of pleural fluid was obtained from a patient at 
Southmead hospital in Bristol. The qPCR inhibition experiments determined that the use of a DNA 
template derived from the clinical sample had no significant impact with either set of primers (nuc 
and 16S rRNA), these experiments also established that the pleural fluid used did not contain a 
background level of S. aureus and was therefore suitable for the following experiments to 
determine the efficacy of the complete BB+P/C method. 
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To determine the impact of the clinical sample of the efficacy of the BB+P/C method and 
associated qPCR analysis combined, the pleural fluid was spiked with S. aureus JE2 prior to the 
extraction and the DNA extracts were compared against spiked samples of PBS which were 
processed in parallel. This experiment found no significant difference on the amount of S. aureus 
JE2 detected in the clinical samples compared to the PBS samples, showing that the BB+P/C 
method is a proficient method to use for the extraction microbial DNA from clinical samples. 
A dilution series of the relevant plasmid standard was also included in each qPCR run for these 
samples, this permitted absolute quantification of the number of cells in each initial sample. This 
was successful and could be very useful for future studies using this method, however there were 
several caveats recognised. The first is that only a fraction of each sample was run in qPCR, so 
results were statistically revised to determine the number of cells in the initial sample, this provides 
an opportunity for any error to be magnified after qPCR analysis. There were also issues in 
determining the accuracy of the absolute quantification step as the precise number of cells 
expected to be in each sample was unknown. Finally, there were issues with calculating the 
number of cells in the samples analysed with the 16S rRNA primers as different microorganisms 
have variable copy numbers of the 16S rRNA gene, producing difficulty when converting from copy 
number in a sample to the number of cells present. 
Ultimately, this project resulted in an extraction method capable of extracting microbial DNA from 
low yield clinical samples. The method is not impacted by whether the sample is fresh or frozen 
and is highly reliable, with very little variation between results produced from identical samples. 
Each primer set used for qPCR also has an associated plasmid standard which can be used for 
absolute quantification of the number of cells in the initial samples used.  
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8. Future directions 
There is scope for further work into the development of this DNA extraction protocol. One 
suggested investigation would be to perform the BB+P/C DNA extraction on a microbial community 
standard, such as the ones available from ZymoBiomics [89]. Using a mock community of known 
quantities such as this would allow direct comparison between the amount of each organism 
present in the sample before the extraction against the quantity detected by qPCR analysis. Being 
a diverse, mixed community, this would also allow comparison of extraction efficiencies between 
different types of microorganisms (for example, Gram-positive vs Gram-negative). This could be 
completed by sequencing the DNA extracts using the 16S rRNA primers, followed by 16S microbial 
analysis which could be carried out using pre-existing pipelines, such as Mothur [90]. This 
approach could also be used in future studies in order to determine the proportion of a specific 
organism within the sample, however it should be noted that correcting for 16S rRNA gene copy 
number remains an unsolved problem in microbiome studies [75]. These mock communities would 
also be useful for confirming the accuracy of the absolute quantification described in this project. 
Another useful endeavour to advance the work completed in this project would be to use the 
method on bronchoalveolar lavage (BAL) samples and analyse this ‘gold-standard’ sample type in 
the same way that pleural fluid was used in this project. The availability of ethically approved BAL 
was a major caveat of this project, however a future study using BAL rather than pleural fluid could 
strengthen the results found in this study regarding its use on pulmonary clinical samples. If using 
BAL samples, it would be important to not use ‘blind-bronchoscopy’ to acquire the samples as this 
method is unable to provide definitive information on the location of the BAL within the lungs. It is 
recommended that samples are acquired through either electromagnetic navigational 
bronchoscopy (ENB) or fibreoptic bronchoscopy. 
A further obstacle which could be worth future investigation is the relative quantity of host DNA 
compared to microbial DNA in each clinical sample. Human cells have significantly more genomic 
DNA than most bacterial species (largest sequenced bacterial genome = 14.7 million base pairs 
[91]; human genome = 14.8 billion base pairs [92]). This was managed during this project by only 
using lower concentrations (<1,000ng/µl) of each DNA template to reduce any impacts the host 
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DNA might have on the qPCR analysis. Human cells lyse far more readily than bacterial cells, so 
could be selectively lysed using low levels of detergent, however it must be noted that this would 
also remove all extracellular DNA from the sample. The issue of host DNA presence could also be 
mitigated by post-extraction procedures, such as the use of dPCR for analysis, or by performing 
statistical techniques such as decontam [93] to identify and remove contaminating sequences from 




9.1. Optimisation of primers for traditional PCR: 
 
Temperature gradient PCR runs were carried out on the 16S rRNA primer set and the nuc_Hoegh 
primer set using JE2 genomic DNA as a template. This was done in order to determine the optimal 
annealing temperature (Ta) for each set of PCR primers. The bands on the left (1-8) show the PCR 
product from the run using the 16S rRNA primer set, the temperature gradient ranged from 50°C to 
35°C. Band 5 was selected as the optimal Ta for the 16S rRNA primers (39.5°C). The bands on the 
right (9-16) show the PCR product from the run using the nuc_Hoegh primer set, the temperature 
gradient ranged from 60°C to 45°C. Band 10 was selected as the optimal Ta for the nuc_Hoegh 
primers (58.2°C). The gel was 1% agarose and electrophoresis conditions were: 300mA, 90V, 45 
minutes. 5ul of PCR product was loaded per well and a 1kb ladder was used.  
1     2     3     4    5     6     7     8 
9    10   11  12   13  14   15   16 
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9.2. Plasmid map of 16S rRNA gene in TOPO TA pCR2.1 
 
 
Plasmid map of the 16S rRNA gene from Vibrio natriegens in a TOPO TA pCR2.1 plasmid. The 
16S rRNA gene is shown in blue with V4 region highlighted in yellow. The TOPO TA pCR2.1 
vector is shown in black. Produced using SnapGene viewer [94].  
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9.3. Plasmid map of S. aureus nuc gene in pCDF-Duet-1 
 
 
Plasmid map of the nuc gene from Staphylococcus aureus in a pCDF-Duet-1 plasmid. The nuc 
gene is shown in blue, the pCDF-Duet-1 vector is shown in black. Produced using SnapGene 
viewer [94].  
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9.4. nuc amplicon for production of p(nuc) standard 















The ATAT repeats are to assist the action of restriction enzymes. Restriction sequences are at the 
5’ end of each primer. A small region of DNA beyond the nuc gene was included at both the 5’ and 
3’ ends to ensure the entirety of the nuc gene was included in the amplicon. The sequence for the 
nuc gene is shown in red. 
 
9.5. Roche Kit: Lysostaphin vs Metapolyzyme 
  DNA yield (ng/µl) 
  A B C Avg. i. Avg. ii. 
Lysostaphin 
Lys 1 69.0 68.5 68.5 68.67 
71.67 Lys 2 84.4 86.3 86.1 85.60 
Lys 3 61.1 61.7 59.4 60.73 
MetaPolyzyme 
Met 1 81.3 80.0 82.3 81.20 
83.63 Met 2 78.9 78.1 78.4 78.47 
Met 3 92.1 91.9 89.7 91.23 
 
Comparison of DNA yields extracted from 500µl samples of JE2 liquid culture using the Roche 
High Pure PCR Template Preparation DNA extraction kit and either Lysostaphin or MetaPolyzyme 
for enzymatic cellular lysis. DNA yields were quantified using a NanoDrop spectrophotometer. The 
average readings for each biological repeat (Avg. i.) were used to produce an average for each 
enzymatic method (Avg. ii.). A two-tailed, unpaired t-test was performed which found that these two 
enzymatic methods do not produce significantly different yields (P=0.2227; T = 1.4423; N = 6; df = 
4).   
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9.6. Fresh vs frozen 
  DNA yield (ng/µl) 
  A B C Avg. i. Avg. ii. 
Met + kit: Fresh  
1 81.8 82.4 82.0 82.07 
99.38 2 91.2 91.7 92.5 91.80 
3 123.9 119.1 129.8 124.27 
Met + kit: Frozen  
1 94.7 99.2 96.9 96.93 
91.78 2 81.0 83.1 76.8 80.30 
3 93.2 97.9 103.2 98.10 
BB +P/C: Fresh 
1 175.6 199.8 197.4 190.93 
192.83 2 180.5 177.1 203.9 187.17 
3 199.6 199.5 202.1 200.40 
BB + P/C: Frozen 
1 190.3 185.4 184.3 186.67 
191.03 2 192.2 188.1 185.6 188.63 
3 195.6 196.9 200.9 197.80 
Met + P/C: Fresh 
1 186.5 190.2 188.7 188.47 
203.87 2 229.4 231.6 231.7 230.90 
3 194.7 190.6 191.4 192.23 
Met + P/C: Frozen 
1 127.0 114.6 115.2 118.93 
123.14 2 136.0 126.1 129.2 130.43 
3 122.3 118.5 119.4 120.07 
 
Comparison of DNA yields extracted from either fresh or frozen 500µl samples of JE2 liquid culture 
using either MetaPolyzyme + the Roche High Pure PCR Template Preparation DNA extraction kit 
(Met+Kit), the Bead-beating + phenol/chloroform DNA extraction method (BB+P/C), or the 
MetaPolyzyme + phenol/chloroform DNA extraction method (Met+P/C). DNA yields were quantified 
using a NanoDrop spectrophotometer. Three readings were taken for each biological replicate and 
an average was taken (Avg. i.). An average was then taken from the three biological replicates per 
sample (Avg. ii.).  
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9.7. Comparison of kit vs P/C methods 
  DNA yield (ng/µl) 
  A B C Avg. i. Avg. ii. 
Met + Kit 
1 81.3 80.0 82.3 81.20 
83.63 2 78.9 78.1 78.4 78.47 
3 92.1 91.9 89.7 91.23 
BB + P/C 
1 277.2 278.9 281.4 279.17 
262.73 2 2204.6 2152.7 2173.3 2176.87 
3 250.2 251.9 236.8 246.30 
Met + P/C 
1 130.4 132.8 137.0 133.40 
130.01 2 143.9 146.2 148.1 146.07 
3 116.1 107.6 108.0 110.57 
 
Comparison of DNA yields extracted from 500µl samples of JE2 liquid culture using either 
MetaPolyzyme + the Roche High Pure PCR Template Preparation DNA extraction kit (Met+Kit), 
the Bead-beating + phenol/chloroform DNA extraction method (BB+P/C), or the MetaPolyzyme + 
phenol/chloroform DNA extraction method (Met+P/C). DNA yields were quantified using a 
NanoDrop spectrophotometer. An average was taken for each biological replicate (Avg. i.), these 
averages were then used to produce an average for each DNA extraction method (Avg. ii.). 
Results from the biological repeat BB+P/C 2 (red text in table) were omitted due to contamination 
of the sample. 
It should also be noted that these experiments were carried out in parallel with the ‘Roche Kit: 
Lysostaphin vs MetaPolyzyme’ experiments. The three biological repeats which comprised the 
‘Met+Kit’ samples in the ‘Comparison of kit vs P/C methods’ experiments were also the 
‘MetaPolyzyme’ samples in the ‘Roche Kit: Lysostaphin vs MetaPolyzyme’ experiments shown in 
Appendix 9.5.  
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9.8. Comparison of methods using serially diluted culture 
   DNA yield (ng/µl) 
   A B C Avg. i. Avg. ii. 
Neat 
met + kit 
1 81.8 82.4 82.0 82.07 
99.38 2 91.2 91.7 92.5 91.80 
3 123.9 119.1 129.8 124.27 
BB + P/C 
1 175.6 199.8 197.4 190.93 
192.83 2 180.5 177.1 203.9 187.17 
3 199.6 199.5 202.1 200.40 
met + P/C 
1 186.5 190.2 188.7 188.47 
203.87 2 229.4 231.6 231.7 230.90 
3 194.7 190.6 191.4 192.23 
1 in 10 
met + kit 
1 16.5 15.8 15.1 15.80 
15.82 2 16.5 14.7 19.2 16.80 
3 14.8 15.3 14.5 14.87 
BB + P/C 
1 31.9 36.8 38.8 35.83 
41.32 2 43.1 41.6 44.2 42.97 
3 45.4 45.2 44.9 45.17 
met + P/C 
1 17.1 17.3 19.9 18.10 
17.17 2 20.4 21.0 21.7 21.03 
3 14.1 12.1 10.9 12.37 
1 in 100 
met + kit 
1 13.7 15.9 15.3 14.97 
8.48 2 2.7 0.3 0.2 1.07 
3 4.8 11.1 12.3 9.40 
BB + P/C 
1 17.7 10.9 9.4 12.67 
11.67 2 8.8 7.7 7.4 7.97 
3 14.2 15.2 13.7 14.37 
met + P/C 
1 13.0 15.4 19.5 15.97 
10.53 2 9.7 8.0 7.6 8.43 
3 7.6 7.0 7.0 7.20 
 
Comparison of DNA yields extracted from 500µl samples of JE2 as either neat liquid culture, 
diluted 1 in 10, or diluted 1 in 100. Extractions were performed using either MetaPolyzyme + the 
Roche High Pure PCR Template Preparation DNA extraction kit (Met+Kit), the Bead-beating + 
phenol/chloroform DNA extraction method (BB+P/C), or the MetaPolyzyme + phenol/chloroform 
DNA extraction method (Met+P/C). DNA yields were quantified using a NanoDrop 
spectrophotometer. Three readings were taken for each biological replicate and an average taken 
(Avg. i.). An average was then taken from the three biological replicates per sample (Avg. ii.). 
It should also be noted that these experiments were carried out in parallel with the ‘Fresh vs frozen’ 
experiments and that the ‘neat’ samples used in this experiment for all three DNA extraction 
methods are the same samples which comprised the ‘fresh’ samples for all three DNA extraction 
methods in the fresh vs frozen experiments shown in Appendix 9.6.  
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9.9. qPCR comparison of methods using serially diluted culture 
  Cq values 
  1 2 3 Avg. 
Met + kit 
Neat 15.49 16.08 15.43 15.67 
1 in 10 23.88 22.68 23.18 23.25 
1 in 100 28.18 27.48 30.90 28.86 
BB + P/C 
Neat 14.52 13.55 12.60 13.56 
1 in 10 17.98 19.73 17.64 18.45 
1 in 100 26.58 25.59 26.23 26.13 
Met + P/C 
Neat 19.24 19.33 19.68 19.42 
1 in 10 24.67 25.13 26.97 25.59 
1 in 100 30.27 30.61 29.13 30.00 
p(16S) 
Neat 13.30 - - 13.30 
1 in 10 17.40 - - 17.40 
1 in 100 21.68 - - 21.68 
Water (NTC) - 30.09 30.64 - 30.36 
 
Cq values for the comparison of DNA extraction methods on serially diluted culture (neat, 1 in 10, 
and 1 in 100) using 16S rRNA primers. Samples included are three technical replicates for all 
dilutions of each of the three DNA extraction methods (Met+kit, BB+P/C, and Met+P/C). Also 
included is the p(16S) standard at the three dilutions (neat, 1 in 10, and 1 in 100), and two qPCR 
grade water non-template control (NTC) samples.  
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9.10. Standardisation of BB+P/C method: Phase lock gel 
Sample 
DNA Quantity (ng/µl) 
Standard 







1 1846.0 1975.9 1949.0 1923.6 
1425.01 396.15 2 1248.7 1211.8 1419.7 1293.4 
3 982.5 1021.7 1169.8 1058.0 
PLG + 
4 2053.9 2081.4 2259.0 2131.4 
2014.81 115.81 5 1979.0 1893.4 1903.4 1925.3 
6 2012.9 1904.0 2046.3 1987.7 
Blank (TSB) 
PLG - 
7 19.4 17.0 25.8 20.7 
19.54 4.12 8 20.5 24.4 21.7 22.2 
9 16.2 12.6 18.3 15.7 
PLG + 
10 28.2 17.3 20.0 21.8 
18.82 4.57 11 16.2 15.6 22.6 18.1 
12 12.3 19.5 17.7 16.5 
 
DNA yields from phase log gel (PLG) tests to determine the effect of PLG on the variability of 
samples. Three technical repeats were performed for each biological sample (1-12), and three 
biological repeats were performed per sample type. Standard deviation was calculated to show 
variation of samples. DNA quantities were measured using a NanoDrop Spectrophotometer. 
 
9.11. LoD experiments 









A B Avg. A B Avg 
N 2 x 107 14.25 14.25 14.25 13.72 13.74 13.73 
1 x 10-1 2 x 106 17.23 17.56 17.40 17.20 17.88 17.54 
1 x 10-2 2 x 105 21.07 21.29 21.18 21.34 20.75 21.05 
1 x 10-3 2 x 104 23.96 24.03 23.99 23.79 24.15 23.97 
1 x 10-4 2 x 103 27.16 26.57 26.87 27.18 28.04 27.61 
1 x 10-5 200 29.12 29.02 29.07 29.42 30.23 29.83 
1 x 10-6 20 31.36 31.02 31.19 30.88 31.24 31.06 
1 x 10-7 2 -1 -1 0.00 31.60 32.11 31.86 
Water NTC 0 -1 -1 0.00 32.15 31.70 31.93 
 
Cq values from extended serial dilution using plasmid standards to determine the limit of detection 
(LoD) of the qPCR analysis stage with each primer set (nuc_qPCR and 16S rRNA). For each 
qPCR reaction, 2µl of each sample at 1x10(n) was used as a DNA template.  
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9.11.2. CFU/ml of JE2 liquid culture for LoD experiments  
Sample CFU/ml 
Number Dilution 1 2 3 Avg. Estimated CFU/ml 
1 Neat TNTC TNTC TNTC - ~1,000,000,000 (1 x 109) 
2 1 x 10-1 TNTC TNTC TNTC - ~100,000,000 (1 x 10
8) 
3 1 x 10-2 TNTC TNTC TNTC - ~10,000,000 (1 x 10
7) 
4 1 x 10-3 TNTC TNTC TNTC - ~1,000,000 (1 x 10
6) 
5 1 x 10-4 TNTC TNTC TNTC - ~100,000 (1 x 10
5) 
6 1 x 10-5 TNTC TNTC TNTC - ~10,000 (1 x 10
4) 
7 1 x 10-6 1024 1052 1020 1032.00 ~1,000 (1 x 10
3) 
8 1 x 10-7 110 117 130 119.00 ~100 (1 x 10
2) 
9 1 x 10-8 9 10 11 10.00 ~10  
10 1 x 10-9 0 0 1 0.333 ~1 
11 1 x 10-10 0 0 0 0.00 0 
12 1 x 10-11 0 0 0 0.00 0 
13 1 x 10-12 0 0 0 0.00 0 
14 1 x 10-13 0 0 0 0.00 0 
15 1 x 10-14 0 0 0 0.00 0 
B Blank (TSB) 0 0 0 0.00 0 
 
CFU/ml plate counts from a serial dilution of JE2 liquid culture used for LoD experiments. The 
average CFU/ml counts for later dilutions (1x10-6 to 1x10-8) were extrapolated to predict the 
estimated CFU/ml of earlier dilutions in the series (N to 1x10-5).  
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9.11.3. LoD of BB+P/C DNA extraction and qPCR stage combined 
  Cq value 
  nuc 16S 
  A B Avg. A B Avg. 
CFU/ml 
of JE2 
100,000,000 11.29 11.30 11.30 10.38 10.26 10.32 
10,000,000 16.05 15.85 15.95 15.12 15.29 15.21 
1,000,000 21.36 21.22 21.29 24.08 24.09 24.09 
100,000 25.12 25.25 25.19 27.95 28.08 28.02 
10,000 25.47 25.58 25.53 29.11 28.88 29.00 
1,000 27.67 27.71 27.69 30.57 31.12 30.85 
100 27.88 28.15 28.02 31.07 31.07 31.07 
10 27.19 27.12 27.16 29.71 29.30 29.51 
1 27.29 27.09 27.19 29.82 29.96 29.89 
Blank (TSB) 29.18 29.01 29.10 33.14 35.07 34.11 
NTC (Water) -1 -1 0.00 30.33 30.18 30.26 
 
Raw Cq values from qPCR to determine the limit of detection (LoD) of the BB+P/C and qPCR 
stages combined. qPCR was performed using both 16S rRNA primers and nuc_qPCR primers. 
 
9.12. Clinical sample inhibition experiments: qPCR 
9.12.1. PF and p(nuc): 
 Cq value 
  A B Avg. 
p(nuc) 15.29 15.42 15.35 
p(nuc) + PF 15.47 16.09 15.78 
PF 29.55 30.84 30.19 
Water 30.37 30.72 30.54 
 
Raw Cq values from qPCR test to determine impact of pleural fluid on the qPCR analysis stage 
using nuc_qPCR primers. 
9.12.2. PF and 16S: 
 Cq value 
 A B Avg. 
p(16S) 18.72 17.13 17.92 
p(16S) + PF 17.69 18.46 18.07 
PF 24.33 24.61 24.47 
Water 28.41 28.94 28.68 
 
Raw Cq values from qPCR test to determine impact of pleural fluid on the qPCR analysis stage 
using 16S rRNA primers.  
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9.13. Clinical sample inhibition experiments: BB+P/C DNA extraction and qPCR 
analysis stages combined 
9.13.1. JE2 spike – nuc primers 
 Cq value 
 A B C D E F Avg. 
PBS  26.00 26.23 25.65 25.48 25.97 25.67 25.84 
PBS + JE2  15.06 15.35 15.66 15.72 16.43 16.53 15.79 
PF  24.48 23.36 24.90 23.90 22.74 24.14 23.92 
PF + JE2  15.42 15.53 18.76 18.93 13.27 13.52 15.90 
p(nuc) 2x107  12.50 11.50 - - - - 12.00 
p(nuc) 2x106  13.75 14.36 - - - - 14.05 
p(nuc) 2x105  16.38 16.11 - - - - 16.24 
Water (NTC)  -1.00 -1.00 -1.00 -1.00 - - 0.00 
 
Raw Cq values from qPCR test to determine impact of pleural fluid on the BB+P/C extraction 
method when using nuc primers. A set of pleural fluid based samples and a set of PBS based 
samples were produced. Half of each set was spiked with S. aureus strain JE2. All samples were 
put through the BB+P/C DNA extraction protocol and analysed by qPCR using nuc_qPCR primers 
alongside the p(nuc) standard at three dilutions and a non-template control of qPCR grade water. 
9.13.2. JE2 spike – 16S rRNA primers 
 Cq value 
 A B C D E F Avg. 
PBS  34.32 31.96 32.02 34.19 33.59 32.59 33.11 
PBS + JE2  20.99 21.12 21.10 20.80 21.07 20.81 20.98 
PF  25.72 24.57 26.23 24.33 24.52 26.10 25.25 
PF + JE2  21.28 21.39 21.00 21.42 21.49 20.74 21.22 
p(16S) 2x107  17.25 16.91 - - - - 17.08 
p(16S) 2x106  20.63 20.21 - - - - 20.42 
p(16S) 2x105  23.90 23.41 - - - - 23.66 
Water (NTC)  32.05 33.11 32.27 31.77 - - 32.30 
 
Raw Cq values from qPCR test to determine impact of pleural fluid on the BB+P/C extraction 
method when using 16S rRNA primers. A set of pleural fluid based samples and a set of PBS 
based samples were produced. Half of each set was spiked with S. aureus strain JE2. All samples 
were put through the BB+P/C DNA extraction protocol and analysed by qPCR using 16S rRNA 
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